

1           **Mitochondrial MICOS complex genes, implicated in hypoplastic left heart**  
2           **syndrome, maintain cardiac contractility and actomyosin integrity**

3 **Authors:** Katja Birker<sup>1,#</sup>, Natalie J. Kirkland<sup>2,#</sup>, Jeanne L. Theis<sup>3,#</sup>, Zachary C. Fogarty<sup>4</sup>,  
4 Maria Azzurra Missinato<sup>1</sup>, Sreehari Kalvakuri<sup>1</sup>, Paul Grossfeld<sup>5</sup>, Adam J. Engler<sup>2</sup>, Karen  
5 Ocorr<sup>1</sup>, Timothy J. Nelson<sup>6</sup>, Alexandre R. Colas<sup>1</sup>, Timothy M. Olson<sup>7</sup>, Georg Vogler<sup>1,\*</sup>,  
6 and Rolf Bodmer<sup>1,\*</sup>

7 **Affiliations:**

8 <sup>1</sup> Development, Aging and Regeneration Program, Center for Genetic Disorders & Aging  
9 Research, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA

10 <sup>2</sup> Department of Bioengineering, Sanford Consortium for Regenerative Medicine,  
11 UCSD, School of Medicine, La Jolla, CA, USA

12 <sup>3</sup> Cardiovascular Genetics Research Laboratory, Mayo Clinic, Rochester, MN, USA

13 <sup>4</sup> Division of Computational Biology, Department of Quantitative Health Sciences, Mayo  
14 Clinic, Rochester, MN, USA

15 <sup>5</sup> Department of Pediatrics, UCSD School of Medicine, La Jolla, Rady's Hospital MC  
16 5004, San Diego, CA, USA

17 <sup>6</sup> Center for Regenerative Medicine, Division of Pediatric Cardiology, Department of  
18 Pediatric and Adolescent Medicine, Division of General Internal Medicine, Department  
19 of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic,  
20 Rochester, MN, USA.

21 <sup>7</sup> Department of Cardiovascular Medicine, Division of Pediatric Cardiology, Department  
22 of Pediatric & Adolescent Medicine, Cardiovascular Genetics Research Laboratory,  
23 Mayo Clinic, Rochester, MN, USA.

24 **# Co-First authors**

25 **\* Co-corresponding author:** Dr. Rolf Bodmer and Dr. Georg Vogler, Development,  
26 Aging and Regeneration Program, Center for Genetic Disorders and Aging Research,  
27 Sanford Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd., La  
28 Jolla, CA 92037, USA; Emails: [rolf@sbpdiscovery.org](mailto:rolf@sbpdiscovery.org); [gvogler@sbpdiscovery.org](mailto:gvogler@sbpdiscovery.org)

29

30 **Key words:** Congenital heart disease, *Drosophila*, *CHCHD3*, *CHCHD6*, *SAM50*,  
31 *ATPsynthase*, HLHS, human iPSC, cardiomyocytes

32

## 33 ABSTRACT

34 Hypoplastic left heart syndrome (HLHS) is a severe congenital heart disease (CHD) with  
35 a likely oligogenic etiology, but our understanding of the genetic complexities and  
36 pathogenic mechanisms leading to HLHS is limited. We therefore performed whole  
37 genome sequencing (WGS) on a large cohort of HLHS patients and their families to  
38 identify candidate genes that were then tested in *Drosophila* heart model for functional  
39 and structural requirements. Bioinformatic analysis of WGS data from an index family  
40 comprised of a HLHS proband born to consanguineous parents and postulated to have a  
41 homozygous recessive disease etiology, prioritized 9 candidate genes with rare,  
42 predicted damaging homozygous variants. Of the candidate HLHS gene homologs  
43 tested, cardiac-specific knockdown (KD) of mitochondrial MICOS complex subunit  
44 *dCHCHD3/6* resulted in drastically compromised heart contractility, diminished levels of  
45 sarcomeric actin and myosin, reduced cardiac ATP levels, and mitochondrial fission-  
46 fusion defects. Interestingly, these heart defects were similar to those inflicted by cardiac  
47 KD of ATP synthase subunits of the electron transport chain (ETC), consistent with the  
48 MICOS complex's role in maintaining cristae morphology and ETC complex assembly.  
49 Analysis of 183 genomes of HLHS patient-parent trios revealed five additional HLHS  
50 probands with rare, predicted damaging variants in *CHCHD3* or *CHCHD6*. Hypothesizing  
51 an oligogenic basis for HLHS, we tested 60 additional prioritized candidate genes in these  
52 cases for genetic interactions with *CHCHD3/6* in sensitized fly hearts. Moderate KD of  
53 *CHCHD3/6* in combination with *Cdk12* (activator of RNA polymerase II), *RNF149* (E3  
54 ubiquitin ligase), or *SPTBN1* (scaffolding protein) caused synergistic heart defects,  
55 suggesting the potential involvement of a diverse set of pathways in HLHS. Further  
56 elucidation of novel candidate genes and genetic interactions of potentially disease-  
57 contributing pathways is expected to lead to a better understanding of HLHS and other  
58 CHDs.

## 59 INTRODUCTION

60 Hypoplastic left heart syndrome (HLHS) is a birth defect that accounts for 2-4% of  
61 congenital heart defects (CHDs), equal to 1000-2000 HLHS births in the United States  
62 per year. HLHS has been proposed to be caused by genetic, epigenetic, or environmental  
63 factors (Crucean *et al.*, 2017; Liu *et al.*, 2017; Yagi *et al.*, 2018; Grossfeld *et al.*, 2019).  
64 The severe cardiac characteristics of HLHS include aortic and mitral stenosis or atresia,  
65 and reduced size of the left ventricle and aorta; however, there is a spectrum of cardiac  
66 phenotypes that can underly HLHS pathophysiology (Theis, Hrstka, *et al.*, 2015; Crucean  
67 *et al.*, 2017; Mussa and Barron, 2017; Grossfeld *et al.*, 2019). If not treated with  
68 reconstructive heart surgeries or cardiac transplantation, infants born with HLHS will not  
69 survive (Grossfeld *et al.*, 2019). To date, the standard treatment for this disease is a three-  
70 stage surgical procedure, which begins neonatally and aims overall to achieve right  
71 ventricle-dependent systemic circulation and deliver oxygen-poor blood more directly to  
72 the lungs (Mussa and Barron, 2017). Although the surgical procedures correctly divert left  
73 ventricular function to the right ventricle, there is a subgroup of HLHS patients who are at  
74 risk of latent heart failure, which is often preceded by reduced ejection fraction (Altmann  
75 *et al.*, 2000; McBride *et al.*, 2008; Theis, Zimmermann, *et al.*, 2015).

76 Although several studies have examined the molecular underpinnings of HLHS,  
77 the number of genes associated with this disease is small (e.g. *NKX2-5*, *NOTCH1*, *ETS1*,  
78 *MYH6*, *LRP2* and *CELSR1*), and they are not yet conclusively determined as causal for  
79 HLHS (Garg *et al.*, 2005; Ye *et al.*, 2009; Kobayashi *et al.*, 2014; Theis, Hrstka, *et al.*,  
80 2015; Tomita-mitchell *et al.*, 2016; Theis *et al.*, 2020, 2021, 2022). Defining pathogenic  
81 mechanisms has proved elusive given the oligogenic complexity of HLHS. Overall, there  
82 is a great need to functionally evaluate newly emerging HLHS candidate genes to  
83 understand how they may contribute to the molecular, cellular, and morphological  
84 processes underlying HLHS.

85 *Drosophila* is well-suited for modeling genetic underpinnings of CHDs: many of the  
86 genes and gene programs found in the *Drosophila* heart are evolutionarily conserved,  
87 including a core set of cardiogenic transcription factors and inductive factors (e.g. *Nkx2-*

88 *5/tinman*) (Bodmer, 1995; Cripps and Olson, 2002; Bier and Bodmer, 2004; Bodmer and  
89 Frasn, 2010; Ahmad, 2017), approximately 75% of known human disease-causing  
90 genes having fly orthologs (Bodmer and Frasn, 2010; Pandey and Nichols, 2011; Ugur,  
91 Chen and Bellen, 2016), and the developing mammalian and *Drosophila* hearts share  
92 developmental similarities, such as their origin within the mesoderm.

93 Mitochondria have been postulated to play a critical role in HLHS pathogenesis.  
94 For example, a recent study reported that cardiomyocytes derived from iPSCs of HLHS  
95 patients (iPSC-CM), who later developed right ventricular failure, had reduced  
96 mitochondrial concentration, ATP production, and contractile force (Paige *et al.*, 2020).  
97 This study revealed downregulated expression of genes involved in mitochondrial  
98 processes, such as ATP synthesis coupled electron transport. Another study of HLHS  
99 patient-derived iPSC-CMs revealed reduced mitochondrial size, number, and malformed  
100 mitochondrial inner membranes using transmission electron microscopy (Yang *et al.*,  
101 2017). Similarly, an HLHS mouse model with *Sap130* and *Pcdha9* mutations showed  
102 mitochondrial defects manifested as reduced cristae density and smaller mitochondrial  
103 size (Liu *et al.*, 2017). Despite a lack of understanding of the exact mitochondrial  
104 mechanisms underlying HLHS pathogenesis, recent experimental and bioinformatic data  
105 suggest an underlying role of mitochondria in HLHS.

106 Here, a cohort of 183 HLHS proband-parent trios underwent whole genome  
107 sequencing (WGS) to identify candidate genes, including a prioritized consanguineous  
108 family where genes harboring rare, predicted damaging homozygous variants were  
109 investigated (Theis and Olson, 2022). Among the resulting candidate HLHS genes tested  
110 in *Drosophila*, cardiac-specific knockdown (KD) of *CHCHD3/6* (*coiled-coil-helix-coiled-*  
111 *coil-helix-domain-containing protein 6*) of the MICOS (mitochondrial contact site and  
112 cristae organization system) complex exhibited severe heart structure and function  
113 defects. The MICOS complex is an eight-subunit complex in mammals (five in *Drosophila*)  
114 located in the inner mitochondrial membrane that is necessary to maintain cristae  
115 morphology and ATP production. It is closely associated and interacts with SAM50  
116 (sorting and assembly machinery), which is located in the outer mitochondrial membrane  
117 (Ott *et al.*, 2012; Kozjak-Pavlovic, 2017). The MICOS complex's role in cardiac



118 development and functional homeostasis is not known but is likely important for efficient  
119 ATP production. We observed reduced contractility upon cardiac-specific *dCHCHD3/6*  
120 KD, diminished sarcomeric Actin and Myosin levels, as well as severe mitochondrial  
121 morphology defects, which manifested as fragmented and aggregated structures. Similar  
122 phenotypes were observed upon cardiac KD of other MICOS complex genes, as well as  
123 other mitochondrial genes such as ATP synthase (complex V), specifically ATP synthase  
124 B and  $\beta$ . We also found significantly diminished proliferation of human induced pluripotent  
125 stem cell (iPSC)-derived ventricular-like cardiomyocytes (VCMs) upon KD of MICOS  
126 genes. Finally, a family-based candidate gene interaction screen in *Drosophila* revealed  
127 three genes that genetically interact with *dCHCHD3/6*: *Cdk12* (activator RNA polymerase  
128 II activator), *RNF149* (E3 ubiquitin ligase), *SPTBN1* (scaffolding protein). In summary,  
129 *CHCHD3/6* and other components important for mitochondrial homeostasis were  
130 identified as critical for establishing and maintaining cardiac structure and function, and  
131 likely contribute to HLHS and/or latent heart failure following surgical palliation.

## 132 **RESULTS**

### 133 **Family Phenotype**

134 Family 11H is of white ancestry and comprised of a male with HLHS, his parents,  
135 and two siblings, they were all phenotypically characterized by echocardiography and  
136 underwent WGS. A homozygous recessive disease mode of inheritance was postulated  
137 due to reported consanguinity between the mother and father and absence of structural  
138 and myopathic heart disease in the parents. The siblings also had normal  
139 echocardiograms (**Figure 1A**). The 11H proband had latent decline of right ventricular  
140 ejection fraction several years after surgical palliation. In addition to HLHS, he was  
141 diagnosed with developmental delay, cerebral and cerebellar atrophy, white matter loss,  
142 decreased muscle mass, and a body mass index <1%, traits that have previously been  
143 related to mitochondrial dysfunction (Romanello and Sandri, 2016; Alston *et al.*, 2017).

### 144 **Whole Genome Sequencing and Bioinformatics Analysis of 11H family**

145           Array comparative genomic hybridization ruled out a chromosomal deletion or  
146 duplication in the proband. WGS was carried out on genomic DNA samples from the five  
147 family members, based on paired-end reads that passed quality control standards; 99.4%  
148 of the reads mapped to the genome. After marking and filtering out duplicate reads, over  
149 91% of the hg38 human reference genome had coverage. The average depth across the  
150 genome was 63X and an average of 89% of the genome demonstrated a minimal read  
151 depth of 20 reads. Filtering for rare variants that were homozygous in the HLHS proband  
152 revealed nine candidate genes. Three genes had a missense variant (*SZT2*, *MTRR*,  
153 *MBTPS1*) whereas the remaining six genes were found to have a non-coding variant  
154 within the promoter (*CAP1*, *DGKE*), 5' untranslated region (*RHBDL2*, *RNF149*,  
155 *C17orf67*), or intron (*CHCHD6*) (**Supplementary Table 1**) (Marian and Belmont, 2011).  
156 While six of the variants were also found to be homozygous in an unaffected sibling, the  
157 associated candidate genes were not excluded from downstream analyses based on the  
158 postulated oligogenic nature of HLHS, and incomplete penetrance of individual variants,  
159 as observed in a digenic mouse model (Yagi *et al.*, 2018).

## 160 **Candidate HLHS gene knockdown in *Drosophila* reveals requirement for** 161 ***CHCHD3/6* in establishing cardiac structure and function**

162           To test whether the HLHS candidates had significant requirements in the heart, we  
163 utilized the established *Drosophila* heart model and cardiac-specific RNAi KD. First, the  
164 nine candidate genes were assigned their respective *Drosophila* homologs; seven out of  
165 nine of the human HLHS candidate genes had *Drosophila* orthologs (**Figure 1B**) (Hu *et*  
166 *al.*, 2011). The *Drosophila* Gal4-UAS system (Brand and Perrimon, 1993) was used to  
167 test candidate genes for their role in heart function using temporal and/or spatial KD via  
168 RNAi. The *Hand<sup>4.2</sup>*-Gal4 driver was used for initial screening because it is a strong post-  
169 mitotic and heart-specific driver, which is expressed throughout life in the cardiomyocytes  
170 (CMs) and pericardial cells (PCs) (Han and Olson, 2005; Han *et al.*, 2006) (**Figure 1C**).  
171 3-week-old (mid-adult stage) female flies were used to test the seven candidate genes.  
172 *Hand<sup>4.2</sup>*-Gal4 KD of *capt* (actin binding protein, negatively regulating actin filament  
173 assembly), *Dgkepsilon* (Diacyl glycerol kinase, DGKE), and *CHCHD3/6* (Mitochondrial  
174 inner membrane protein of the MICOS complex, required for fusion) produced defects in

175 the fly hearts, such as reduced cardiac output, reduced fractional shortening, and  
176 arrhythmicity (**Figure 1B**). Of those, *CHCHD3/6* KD gave the most severe cardiac defects  
177 with strongly reduced fractional shortening, a measure of cardiac contractility. Systolic  
178 rather than end-diastolic diameter was increased, which suggests systolic dysfunction  
179 (**Supp. Figure 1A-C**). Since reduced contractility was previously shown in animals with  
180 reduced mitochondrial gene expression, we hypothesized *CHCHD3/6* KD may reduce  
181 contractility via a role in mitochondrial function (Bhandari, Song and Dorn, 2015;  
182 Martínez-Morentin *et al.*, 2015; Tocchi *et al.*, 2015).

183 To test how early the cardiac phenotype of *CHCHD3/6* KD manifests in adult  
184 stages, 1-week old *Hand<sup>4.2</sup>-Gal4* KD of *CHCHD3/6* flies were examined, using several  
185 independent RNAi lines for *CHCHD3/6*. These flies also had reduced fractional  
186 shortening, i.e., reduced contractility due to systolic dysfunction (**Figure 1D-F**). This  
187 phenotype was observed in cardiac assays of intact flies (see Methods) (**Supp. Figure**  
188 **1D-F**), as well as in the semi-intact adult heart preparation that lacks neuronal inputs  
189 (SOHA; (M Fink *et al.*, 2009)). To further validate a cardiac-specific role for *CHCHD3/6*,  
190 as opposed to non-autonomous effects from other tissues, we performed KD of  
191 *CHCHD3/6* using *Dot*-Gal4 (expressed in pericardial cells, PC, which also express Hand),  
192 *Mef2* (Myocyte enhancer factor 2)-Gal4 (a pan-muscle driver), or *elav*-Gal4 (a pan-  
193 neuronal driver) (see Methods). A large reduction in fractional shortening was only  
194 observed with the pan-muscle driver that includes cardiac muscle, but not with the PC or  
195 neuronal drivers, confirming a cardiomyocyte-autonomous effect (**Supp. Figure 1J-L**).  
196 Both *CHCHD3/6*<sup>RNAiA</sup> and *CHCHD3/6*<sup>RNAiB</sup> lines had the same predicted off-target gene,  
197 *Duox* but *Hand<sup>4.2</sup>-Gal4* driven KD of *Duox* had no effect on fractional shortening,  
198 confirming that the cardiac effects were due to *CHCHD3/6* KD (**Supp. Figure 1M**).

### 199 **Temporal requirements for *CHCHD3/6* in maintaining heart function**

200 We next sought to understand if *CHCHD3/6* has different temporal requirements  
201 for its effects on heart structure and function, since hearts of operated HLHS patients  
202 often develop reduced ejection fraction and heart failure, including the 11H proband. First,  
203 to assess whether *CHCHD3/6* could have a role in early heart development, we mined

204 embryonic heart-specific single-cell transcriptomic data (Vogler *et al.*, 2021) and found  
205 that *CHCHD3/6* was expressed in *Drosophila* cardioblasts (CBs), along with other  
206 cardiogenic factors (*tinman*, *H15*, and *Hand*) (**Figure 2A**). Next, we analyzed *CHCHD3/6*  
207 mutant embryos for cardiac phenotypes. Late-stage 16-17 *CHCHD<sup>D1</sup> / CHCHD<sup>DefA</sup>* trans-  
208 heterozygous embryos were stained for Mef2 (early mesoderm/muscle-specific  
209 transcription factor) and Slit (secreted protein in the heart lumen) but did not exhibit overt  
210 cardiac specification defects (**Figure 2B**). We used the *tinD*-Gal4 driver (*tinman enhancer*  
211 *D* (Yin, Xu and Frasch, 1997; Xu *et al.*, 1998) to test whether *CHCHD3/6* KD in the dorsal  
212 mesoderm (including cardiac mesoderm) during embryonic stages 10-12 affects  
213 establishment of adult heart function. We reared *tinD-Gal4>CHCHD3/6<sup>RNAiA</sup>* flies at 29°C  
214 throughout life to achieve high KD efficiency but did not observe reduced fractional  
215 shortening or any other functional defects, relative to controls (**Figure 2C, D**). Thus, KD  
216 of *CHCHD3/6* in the embryonic cardiac mesoderm is not sufficient to impact later heart  
217 function.

218 To further investigate the temporal requirement of *CHCHD3/6* during heart  
219 development, we made use of the temperature-dependence of Gal4-mediated KDs (less  
220 KD efficiency at 19°C, greater KD efficiency at 29°C; see **Figure 2E** for experimental  
221 strategy). *Hand<sup>4.2</sup>-Gal4* mediated KD of *CHCHD3/6<sup>RNAiA</sup>* had strong contractility defects  
222 already at 19°C (**Figure 2F**). A weaker RNAi KD line *CHCHD3/6<sup>RNAiC1</sup>* (see **Figure 1D-**  
223 **F**) caused no reduction in fractional shortening at 19°C (**Figure 2F**), whereas at 29°C  
224 fractional shortening was reduced similarly to the stronger KD line 19°C. To examine  
225 different developmental windows, *Hand<sup>4.2</sup>-Gal4>CHCHD3/6<sup>RNAiC1</sup>* flies were shifted from  
226 19°C to 29°C at either early pupal stages or early adult stages (after eclosion) until 1 week  
227 of age when heart function was assessed (**Figure 2E**). Interestingly, both treatments  
228 caused a substantial reduction in fractional shortening, although somewhat less than at  
229 29°C throughout life (**Figure 2G-I**). This suggests that *CHCHD3/6* is not only required  
230 during pupal development, but also at adult stages for maintaining robust heart function.

231 **Cardiac knockdown of *Drosophila* *CHCHD3/6* results in severe reduction of**  
232 **sarcomeric Actin and Myosin levels**

233 The strong heart functional defects upon *CHCHD3/6* KD suggest that the  
234 contractile machinery in cardiomyocytes is severely compromised. To probe for  
235 contractile abnormalities, we examined several sarcomeric components, including  
236 filamentous (F-) Actin, Myosin heavy chain, Obscurin (present at the M-line),  $\alpha$ -Actinin  
237 (present at the Z-line), and Sallimus (Titin component in flies, localized near the Z-line)  
238 (**Figure 3A**). The intensity of F-actin staining with phalloidin was severely diminished in  
239 the working myocardium of *Hand<sup>4.2</sup>-Gal4>CHCHD3/6* KD flies (**Figure 3B-D**, arrows in  
240 **B**). Because *Hand<sup>4.2</sup>-Gal4* expression is less in ostial cardiomyocytes (inflow valves), F-  
241 actin staining in ostial sarcomeres was minimally affected, if at all (**Figures 3B**,  
242 arrowheads). Like F-actin staining, Myosin staining was also dramatically diminished  
243 (**Figure 3E,I**) In contrast, Obscurin and  $\alpha$ -Actinin staining was only moderately reduced  
244 (**Figure 3F,G,J,K**), and Sallimus staining was unaffected (**Figure 3H, L**). These findings  
245 suggest that loss of *CHCHD3/6* function did not abrogate the overall sarcomeric  
246 organization, but instead differentially affected the abundance of individual sarcomeric  
247 proteins. Overall, the strongly diminished F-actin and Myosin levels in cardiac myofibrils  
248 is likely responsible for the diminished contractile capacity of the ATP-dependent  
249 actomyosin network in *CHCHD3/6* KD hearts.

## 250 **Actin polymerization components do not mediate sarcomeric actomyosin** 251 **reduction upon cardiac *CHCHD3/6* knockdown**

252 Due to the strong reduction of F-actin levels observed with reduced *CHCHD3/6*  
253 expression, we hypothesized that globular (G) to F-actin polymerization was disrupted. If  
254 *CHCHD3/6* KD compromises mitochondrial ATP production in high energy-demanding  
255 CMs, the reduced ATP levels could disrupt actin polymerization and lead to reductions in  
256 F-actin and other sarcomeric proteins (Carlier, Pantaloni and Korn, 1984; Korn, Carlier  
257 and Pantaloni, 1987; Carlier, 1998). To test this, we reduced the cardiac expression of  
258 several actin polymerizing and depolymerizing genes (**Supp. Figure 2A**). Cardiac KD of  
259 *Arp2/3*, *gel*, *Chd64*, *WASp*, and *TM1* caused slightly reduced fractional shortening, but  
260 not as severe as with *CHCHD3/6* KD (**Supp. Figure 2A, B**). Moreover, cardiac KD of *Arp*,  
261 *Chd64*, or *WASp* resulted in substantial myofibrillar disorganization, including gaps, but  
262 did not appear to produce the *CHCHD3/6* KD-like reduction in sarcomeric F-actin levels

263 (WASp example shown in **Supp. Figure 2C**). Overall, KD of any of these genes involved  
264 in F-actin polymerization could not recapitulate the reduced myocardial F-actin intensity  
265 with normal sarcomeric patterning seen with *CHCHD3/6* KD. Therefore, it appears  
266 unlikely that defects in actin polymerization mediate the effects of *CHCHD3/6* KD.

### 267 ***CHCHD3/6* knockdown in flight or heart muscles results in defective mitochondria**

268 Next, we hypothesized that the reduced contractile capacity and altered F-actin and  
269 Myosin in *CHCHD3/6* KD hearts was due to reduced mitochondrial function. We first  
270 examined mitochondrial integrity and sarcomeric actin staining in indirect flight muscles  
271 (IFMs), since their mitochondria are easily visualized due to their large size. Upon  
272 *CHCHD3/6* KD in IFMs using the pan-muscle driver *Mef2-Gal4*, we observed reduced F-  
273 actin staining and diminished sarcomere pattern definition (**Figure 4A**), similar to the  
274 cardiac phenotype (**Figure 3B**). This further indicated that the *CHCHD3/6* KD phenotype  
275 is not specific to cardiac tissue, but likely affects all muscles. We then examined  
276 mitochondrial integrity upon *CHCHD3/6* KD in IFMs expressing Mito::GFP (complex IV),  
277 and with antibodies against ATP synthase (complex V). Strikingly, Mito::GFP and ATP  
278 synthase staining revealed mitochondrial defects as manifested in aggregates (**Figure 4B-**  
279 **E**), which is suggestive of an imbalance between fusion and fission.

280 Next, we assayed ATP synthase staining in *Hand<sup>4.2</sup>-Gal4>CHCHD3/6<sup>RNAiA</sup>* hearts.  
281 We again observed mitochondrial aggregates, along with reduced F-actin and ATP  
282 synthase staining, relative to controls (**Figure 4F-I**). Furthermore, *Hand<sup>4.2</sup>-Gal4*,  
283 *Mito::GFP>CHCHD3/6<sup>RNAiA</sup>* hearts also exhibited mitochondrial aggregates and reduced  
284 intensity of Mito::GFP (**Figure 4G-I**). Taken together, these data show that *CHCHD3/6* KD  
285 disrupts cardiac mitochondrial morphology and causes the formation of mitochondrial  
286 aggregates.

### 287 **Mitochondrial ATP synthase (complex V) KD causes similar contractile dysfunction** 288 **and diminished sarcomeric F-Actin staining as with *CHCHD3/6* KD**

289 To determine whether KD of other mitochondrial genes impaired contractility and  
290 sarcomeric F-actin accumulation similar to that of *CHCHD3/6* KD, we screened RNAi



291 lines from different mitochondrial functional groups (FlyBase.org GO term mitochondrion:  
292 0005739) using the *Hand<sup>4.2</sup>-Gal-4*; tdtK driver for high-throughput heart imaging analysis  
293 (see Methods; Vogler, 2021). Cardiac KD of 17 of the 21 mitochondrial genes tested  
294 displayed reduced fractional shortening, most commonly due to systolic dysfunction  
295 (**Supplementary Table 2**). However, only KD of ATP synthase subunits reduced both  
296 fractional shortening and F-actin staining (**Figure 4J-M, Supp. Figure 3A**). Remarkably,  
297 F-actin staining in *Hand<sup>4.2</sup>-Gal4*, tdtK>ATPsyn $\beta$ /B<sup>RNAi</sup> hearts resembled that of  
298 *CHCHD3/6* KD, i.e. weakly stained myocardial myofibrils relative to ostial myofibrils  
299 (**Figure 4M**). These findings suggested that the heart dysfunction observed upon  
300 *CHCHD3/6* KD may be mediated via defects in ATP synthase.

### 301 **ATP production is reduced upon *CHCHD3/6* knockdown**

302 Disrupted mitochondrial organization and reduced staining of OXPHOS components  
303 likely impacts ATP production and could explain cardiac functional and structural defects.  
304 We therefore directly measured ATP concentration in 1-week old female hearts with cardiac  
305 *CHCHD3/6* KD. We observed reduced ATP levels upon *CHCHD3/6* KD compared to  
306 controls, and these ATP levels were similar to those measured in response to cardiac *ATP-*  
307 *syn $\beta$*  KD (**Figure 4N**). This further strengthens the hypothesis that the cardiac functional  
308 deficits in contractility induced by *CHCHD3/6* KD are due to mitochondrial defects that  
309 considerably reduce ATP levels in the heart necessary to build and maintain myofibrils.

### 310 ***CHCHD3/6* knockdown in all muscle cells is lethal or reduces climbing ability**

311 To further characterize the impact of *CHCHD3/6* KD induced mitochondrial defects  
312 on muscle function, we assessed locomotive ability. When reared throughout  
313 development at 25°C, Mito::GFP; *Mef2*>*CHCHD3/6*<sup>RNAiA</sup> flies were pupal lethal. However,  
314 with a moderate strength RNAi line (Mito::GFP; *Mef2*>*CHCHD3/6*<sup>RNAiC1</sup>) flies did eclose,  
315 but with reduced viability, especially for males (**Supp. Figure 3B**). Flies are negatively  
316 geotactic and will rapidly climb up the sides of a vial when tapped down. In 1-week of  
317 age, male and female Mito::GFP; *Mef2*>*CHCHD3/6*<sup>RNAiC1</sup> flies, this activity was greatly  
318 reduced compared to controls (**Supp. Figure 3C**), supporting the hypothesis that  
319 *CHCHD3/6* KD reduces muscle function.

320 **Knockdown of SAM50 and Mitofilin cause cardiac defects, and SAM50 genetically**  
321 **interacts with CHCHD3/6**

322 To further explore the role of the MICOS complex to maintain myofibrillar structure,  
323 we tested five MICOS complex-associated components for their requirement in cardiac  
324 contractility and sarcomeric F-actin levels (**Figure 5A**). *Hand<sup>4.2</sup>-Gal4*-mediated KD of  
325 *Mitofilin* or *Sam50* resulted in a significant reduction in fractional shortening, due to  
326 systolic dysfunction, mimicking *CHCHD3/6* KD defect in contractility, whereas *APOOL*,  
327 *Mic13* or *Mic10* KD did not exhibit significant effects (**Figure 5B, Supp. Figure 4A, B**).  
328 Of note, none of these five MICOS associated components displayed detectable  
329 reduction in sarcomeric F-actin staining upon KD (**Supp. Figure 4C**).

330 Subsequently, we tested for genetic interactions between *CHCHD3/6* and MICOS-  
331 associated components, since protein-protein interactions among them have been  
332 previously described (Ding *et al.*, 2015; Li *et al.*, 2016; Tang *et al.*, 2020). To test for  
333 interactions, we generated a *Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD<sup>D1/+</sup>* heterozygote mutant  
334 sensitizer line that had no noticeable cardiac abnormalities (Deng *et al.*, 2016) (**Figure**  
335 **5C**). *Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD<sup>D1/+</sup>* crossed to *Mitofilin* or *Sam50* RNAi did not further  
336 reduce fractional shortening beyond what was observed in response to KD of the  
337 individual genes (**Supp. Figure 4D**). However, we observed an interaction in the  
338 combined *Sam50* KD and *CHCHD<sup>D1/+</sup>* hearts, where F-actin levels were also strikingly  
339 reduced compared to the single KD, similar the *CHCHD3/6* KD (**Figure 5D**). This  
340 suggests that there is a threshold requirement of MICOS/Sam50, which when reached  
341 induces reduced contractility AND diminished F-Actin levels.

342 **Knockdown of MICOS subunits impairs proliferation of human iPSC-derived**  
343 **cardiomyocytes.**

344 We next tested the effects of KD of *CHCHD3/6* and other MICOS-associated  
345 components in human cardiomyocytes (CMs) derived from iPSC (hiPSC-CM). Since  
346 reduced CM proliferation is hypothesized to be a major contributing factor for the etiology  
347 of HLHS (Gaber *et al.*, 2013; Liu *et al.*, 2017; Theis *et al.*, 2020), we focused on  
348 proliferation as our readout. We used small interfering RNA (siRNA) (as in (Theis *et al.*,

349 2020)) to KD genes in hiPSC-CMs. We found that KD of *CHCHD6* and *CHCHD3*, as well  
350 as all other MICOS subunits and *SAM50*, significantly reduced their proliferation in an  
351 EdU incorporation assay (**Supp. Figure 5A, B**), supporting a potential link for *CHCHD6*  
352 and other MICOS subunits in HLHS pathogenesis.

### 353 **Testing of candidate genes prioritized in HLHS probands with *CHCHD3* or *CHCHD6*** 354 **variants reveals novel genetic interactors**

355 Since we found an essential role for *CHCHD3/6* in establishing heart structure and  
356 function in the *Drosophila* heart model with possible relevance for HLHS pathology, we  
357 assessed the presence of variants in additional HLHS family trios. Among the 183 Mayo  
358 Clinic HLHS family trios and pediatric cardiac genomics consortium (PCGC) databank  
359 (Jin *et al.*, 2017), there were three probands with variants in *CHCHD6* (including 11H)  
360 and four with *CHCHD3* variants (**Supplementary Table 3**).

361 The relative abundance of rare, predicted damaging *CHCHD3/6* variants in the  
362 Mayo Clinic cohort, together with the postulated oligogenic nature of HLHS, led us to test  
363 for genetic interactions between *CHCHD3/6* and other HLHS candidate genes.  
364 Specifically, we prioritized candidate genes with rare coding and regulatory variants  
365 identified in HLHS probands who also carried *CHCHD3*- or *CHCHD6*-variants  
366 (**Supplementary Table 4**). We generated a *CHCHD3/6* sensitizer line, *Hand<sup>4.2</sup>-Gal4*,  
367 *tdtK; CHCHD3/6<sup>RNAiC1</sup>*, which at 21°C does not exhibit significant contractility deficits  
368 (**Figure 6A**). We screened 120 RNAi lines representing 60 candidate HLHS genes for  
369 genetic interactions and identified three hits that had contractility defects only when co-  
370 knocked down with *CHCHD3/6<sup>RNAiC1</sup>* at 21°C (**Figure 6B**). *Cdk12* (human ortholog:  
371 *CDK12*) has been shown to activate RNA polymerase II to regulate transcription  
372 elongation (Bartkowiak *et al.*, 2010), *Goliath* (human ortholog: *RNF149*) encodes an E3  
373 ubiquitin ligase that localizes to endosomes (Yamazaki *et al.*, 2013) and  *$\beta$ -Spectrin*  
374 (human ortholog: *SPTBN1*) is a scaffolding protein that links the actin cytoskeleton to the  
375 plasma membrane. KD of *Cdk12* in combination with *CHCHD3/6* KD also led to greater  
376 lethality of elcosed flies at 1 week-of-age compared to individual gene KD (**Figure 6C**).  
377 While interestingly, we found that co-KD of  *$\beta$ -Spectrin* and *CHCHD3/6<sup>RNAiC1</sup>* at 21°C was

378 the only combination that also diminished F-actin and Myosin staining, similar to co-  
379 *CHCHD3/6*<sup>RNAiA</sup> KD (**Figure 6D**). In summary, our approach using a sensitized screening  
380 strategy to interrogate genetic interactions between patient-specific candidate genes is a  
381 powerful tool to identify novel interactions that are potentially involved in the oligogenic  
382 ethology of HLHS and other CHDs.

## 383 **DISCUSSION**

384 HLHS is characterized by a small left heart, including reduced left ventricle size  
385 and mitral and/or atrial atresia or stenosis, and aortic hypoplasia, collectively obstructing  
386 systemic blood flow (Tchervenkov *et al.*, 2006). As a consequence, newborns cannot  
387 sustain systemic blood flow for more than a few days and therefore require treatment  
388 soon after birth. There is a need for improved therapies to treat HLHS patients, and this  
389 requires a better understanding of the biology behind HLHS pathogenesis. Here, we  
390 probed the genetic basis of HLHS using WGS and powerful bioinformatic gene variant  
391 prioritization in a large cohort of HLHS proband-parent trios combined with model system  
392 validation.

393 The 11H family was prioritized because of consanguinity, implicating a  
394 homozygous recessive mode of inheritance that resulted in a short list of nine candidate  
395 genes. These candidate genes were probed in *Drosophila* and iPSC-CMs for a potential  
396 role in cardiomyocyte development and function, to gain new insights into HLHS and  
397 CHDs in general. Among these HLHS gene candidates, we focused on *CHCHD3/6*, which  
398 has not been previously studied in the heart, and which had striking cardiac functional  
399 and structural defects in *Drosophila*. Specifically, the preliminary gene screen  
400 demonstrated that *CHCHD3/6* cardiac-specific KD caused reduced contractility and  
401 decreased sarcomeric F-Actin and Myosin staining.

402 Our data suggest that *CHCHD3/6* is necessary during larval and early adult stages  
403 to maintain contractility in the adult heart. This is relevant since patients with HLHS have  
404 both structural heart disease and risk for later myocardial failure (Theis, Zimmermann, *et*  
405 *al.*, 2015). The prevailing “no flow, no grow” hypothesis for HLHS pathogenesis surmises  
406 that reduced blood flow in the fetal heart causes underdevelopment of the left ventricle

407 (Goldberg and Rychik, 2016; Grossfeld *et al.*, 2019). A reduced ability for the heart to  
408 contract in utero, due to reduced *CHCHD6* activity, could contribute to decreased  
409 ventricular blood flow in the embryo, resulting in an abnormally small left ventricle.  
410 Moreover, reduced *CHCHD6* activity could compromise right ventricular function later in  
411 life (Theis, Hrstka, *et al.*, 2015; Theis, Zimmermann, *et al.*, 2015). In fact, the 11H proband  
412 exhibited mildly reduced right ventricular ejection fraction several years after successful  
413 surgical palliation. Consistent with our model system, *CHCHD6* deficiency could result in  
414 cumulative impairment of mitochondrial function, leading to contractile dysfunction (Sun,  
415 Youle and Finkel, 2016).

416 *CHCHD3/6* KD in the fly heart led to mitochondrial aggregates, with reduced ATP  
417 synthase (complex V) levels, and consequently impaired ATP production. Mitochondrial  
418 aggregates or fragments could be indicative of an imbalance between fission and fusion.  
419 It has previously been reported that *CHCHD3* KD in HeLa cells resulted in fragmented  
420 mitochondria that was due to improper mitochondrial fusion (Darshi *et al.*, 2011). It has  
421 also been demonstrated in yeast that individual or combinatorial loss of MICOS complex  
422 proteins disrupt cristae morphology (Friedman *et al.*, 2015), thus suggesting a mechanism  
423 by which *CHCHD3/6* loss could mediate HLHS pathogenesis. Furthermore, we identified  
424 a genetic interaction between *SAM50* and *CHCHD3/6* that leads to a contractile deficit  
425 and diminished sarcomeric F-Actin. Recent findings demonstrate that *SAM50* directly  
426 interacts with *Mic19*, the mammalian ortholog of *CHCHD3*, to mediate inner and outer  
427 membrane bridging and cristae morphology (Tang *et al.*, 2020).

428 Our data further suggest that ETC Complex V/ ATP synthase is a potential  
429 downstream effector of *CHCHD3/6* and MICOS complex function. Individual KD of ATP  
430 synthase subunits resulted in reduced fractional shortening and reduced sarcomeric  
431 actin. As a result, we hypothesize reduced *CHCHD3/6* expression affects ETC function,  
432 specifically ATP synthase, leading to reduced ATP production. OXPHOS complex  
433 assembly has been shown to be disrupted upon MICOS depletion, and we speculate ATP  
434 synthase may be disrupted when *CHCHD3/6* is reduced (Cogliati, Enriquez and  
435 Scorrano, 2016). Consistent with this, we observe depletion of ATP synthase levels upon  
436 *CHCHD3/6* KD.

437 Finally, we tested a potential oligogenic basis of HLHS in our family-based  
438 *CHCHD3* and *CHCHD6* interaction screen and identified three hits that reduced fractional  
439 shortening only in conjunction with *CHCHD3/6*, but not on their own. Co-KD of *Cdk12* and  
440 *CHCHD3/6* also reduced fractional shortening, and caused greater lethality relative to  
441 *Cdk12* KD alone. *Cdk12* activates RNA polymerase II to regulate transcription elongation  
442 (Bartkowiak *et al.*, 2010). We postulate that since *CHCHD3/6* is a nuclear-encoded gene,  
443 reducing transcription with *Cdk12* KD could decrease *CHCHD3/6* levels in a background  
444 where *CHCHD3/6* activity is already compromised. Alternatively, reduced transcription of  
445 other nuclear genes associated with ATP production in combination with *CHCHD3/6* KD  
446 could further reduce ATP levels enough to cause contractility defects. In support of this,  
447 a study examining the effects of RMP (RNA polymerase II subunit 5-mediating protein)  
448 found that mice with cardiac-specific *Rpm* KO exhibited reduced fractional shortening and  
449 ATP levels, which were attributed to a reduction in mRNA and protein levels of the  
450 mitochondrial biogenesis factor PGC1 $\alpha$  (Zhang *et al.*, 2019). The second hit, *Goliath*, is  
451 an endosomal ubiquitin E3 ligase. Although *Goliath* has been implicated in endosomal  
452 recycling (Yamazaki *et al.*, 2013), its role in *Drosophila* mitophagy *in vivo* has not been  
453 examined. Reduced cardiac contractility with co-KD of *Gol* and *CHCD3/6* could result  
454 from impaired mitophagy and reduced mitochondrial biogenesis. Together, the  
455 accumulation of damaged mitochondria can reduce ATP content required for contraction  
456 (Palikaras and Tavernarakis, 2014; Palikaras, Lionaki and Tavernarakis, 2015). The third  
457 hit,  *$\beta$ -Spectrin*, acts as a scaffolding protein. Recent data suggests that the human  
458 ortholog, SPTBN1 (Nonerythroid spectrin  $\beta$ ) influences SPTAN1 (Nonerythroid spectrin  
459  $\alpha$ ) levels, which has a calmodulin binding domain (Ackermann and Brieger, 2019).  
460 Therefore, decreased  *$\beta$ -Spec* expression could reduce Calmodulin levels, thereby  
461 reducing contractility due to the combined reduction in Ca<sup>2+</sup> handling and *CHCHD3/6* KD-  
462 induced reduced ATP levels.

463 In summary, we have identified a novel mechanism potentially involved HLHS  
464 pathogenesis, starting by analyzing WGS data from a prioritized family and large cohort  
465 of HLHS patients, followed by functional testing *in vivo* using the *Drosophila* heart model  
466 and *in vitro* using human iPSC-derived CMs. Compromised contractile capacity,  
467 diminished sarcomeric F-Actin and Myosin accumulation, and mitochondrial dysfunction



468 in *CHCHD3/6* KD *Drosophila* hearts are promising phenotypes that could contribute to  
469 early HLHS manifestations or heart failure complications later in life. Further examination  
470 of the interactions between the MICOS complex and other emerging candidate genes will  
471 identify novel gene functions and pathways that contribute to HLHS pathogenesis.  
472 Furthermore, a detailed elucidation of novel candidate genes and genetic interactions  
473 based on patient-specific rare potentially damaging variants is expected to lead to gene  
474 networks that are relevant for HLHS and other CHDs.

#### 475 **Acknowledgments**

476 We gratefully acknowledge the patients and families who participated in this study. We  
477 thank Marco Tamayo and Bosco Trinh for excellent technical assistance. This work was  
478 supported by National Institutes of Health (R01 HL054732 to R.B.). This work was also  
479 supported by a grant from the Wanek Foundation at Mayo Clinic in Rochester, M.N., to  
480 J.L.T., T.J.N., T.M.O., R.B. and A.R.C.; by the American Heart Association: AHA  
481 Predoctoral Fellowship (18PRE33960593 to K.B.) and AHA Postdoctoral Fellowship  
482 (20POST35180048 to N.J.K.).

483

## 484 **Materials and Methods**

### 485 **Study subjects**

486 Written informed consent was obtained for the index family and HLHS cohort,  
487 under a research protocol approved by the Mayo Clinic Institutional Review Board.  
488 Cardiac anatomy was assessed by echocardiography.

### 489 **Comparative genomic hybridization**

490 To detect aneuploidy, array comparative genomic hybridization was performed  
491 using a custom 180K oligonucleotide microarray (Agilent, Santa Clara, CA), with a  
492 genome-wide functional resolution of approximately 100 kilobases. Deletions larger than  
493 200 kilobases and duplications larger than 500 kilobases were considered clinically  
494 relevant.

### 495 **Genomic and bioinformatics analysis of 11H family**

496 Genomic DNA was isolated from peripheral white blood cells or saliva. WGS and  
497 variant call annotation were performed utilizing the Mayo Clinic Medical Genome Facility  
498 and Bioinformatics Core. For the family quintet, 101 base pair (bp) or 150 bp paired-end  
499 sequencing was carried out on Illumina's HiSeq 2000 or HiSeq 4000 platforms,  
500 respectively. Reads were aligned to the hg38 reference genome using BWA version  
501 0.7.10 (<http://bio-bwa.sourceforge.net/bwa.shtml>) and duplicate reads were marked using  
502 Picard (<http://picard.sourceforge.net>). Local realignment of INDELS and base quality  
503 score recalibration were then performed using the Genome Analysis Toolkit version 3.4-  
504 46 (GATK) (McKenna *et al.*, 2010). SNVs and INDELS were called across all samples  
505 simultaneously using GATK's Unified Genotype with variant quality score recalibration  
506 (VQSR) (Poplin *et al.*, 2018).

507 Variant call format (VCF) files with SNV and INDEL calls from each family member  
508 were uploaded and analyzed using Ingenuity Variant Analysis software (QIAGEN,  
509 Redwood City, CA) where variants were functionally annotated and filtered by an iterative  
510 process. Annotated variants were subject to quality filters and required to pass Variant  
511 Quality Score Recalibration (VQSR) and have a genotype quality score  $\geq 20$ . Variants

512 were excluded if they were located in a simple repeat region identified using tandem  
513 repeats finder (Benson, 1999) or were found to have a minor allele frequency >1% in  
514 gnomAD v2.1 (Karczewski *et al.*, 2020). Second, functional variants were selected,  
515 defined as those that impacted a protein sequence, canonical splice site, microRNA  
516 coding sequence/binding site, or transcription factor binding site within a promoter  
517 validated by ENCODE chromatin immunoprecipitation experiments (Raney *et al.*,  
518 2014). Third, using parental and sibling WGS data, rare, functional variants were then  
519 filtered for those that were homozygous recessive in the proband.

## 520 **Analysis of HLHS cohort for variants in the MICOS complex**

521 WGS was performed on samples from 183 individuals with HLHS and 496 family  
522 members by the Mayo Clinic Medical Genome Facility or Discovery Life Sciences. SNVs  
523 and INDELS that passed quality control were subject to further filtering based upon rarity  
524 (MAF < 0.01) and predicted consequence. Details about the sequencing and subsequent  
525 variant filtering to identify HLHS gene candidates have been previously described (Theis  
526 *et al.*, 2021). Rare variants from the 183 probands were interrogated for variants in  
527 *CHCHD3* and *CHCHD6* to identify variants that arose de novo or were homozygous  
528 recessive, compound heterozygous or X-linked recessive. Next, inherited variants in  
529 these genes were analyzed, but stricter thresholds were required to identify the most  
530 damaging variants. Missense variants were required to have CADD>24 (corresponds to  
531 the upper quartile of the most damaging missense variants) and non-coding variants were  
532 required to have a Position Weight Matrix (PWM) score >0.75 from the Factorbook  
533 database (selecting for variants predicted to disrupt canonical transcription factor binding  
534 sites). In addition to the Mayo Clinic HLHS cohort, the Pediatric Cardiac Genomics  
535 Consortium (PCGC) whole exome sequencing dataset was interrogated for candidate  
536 genes in the MICOS complex in patients with CHD (Jin *et al.*, 2017).

## 537 **Analysis of *CHCHD3* and *CHCHD6* variant carriers**

538 Using robust bioinformatics algorithms as previously described (Theis and Olson,  
539 2022), a broad range of both family-based Mendelian inheritance modeling and cohort-  
540 wide enrichment analyses were applied to identify additional candidate genes in HLHS

541 probands identified to have a rare, predicted-damaging coding or regulatory variant in  
542 *CHCHD3* or *CHCHD6*.

### 543 ***Drosophila* strains and husbandry**

544 *Drosophila* crosses were reared and aged at 25°C, unless otherwise noted.  
545 *Drosophila* orthologs were determined using DIOPT (*Drosophila* RNAi Screening Center  
546 Integrative Ortholog Prediction Tool) which calculates the number of databases that  
547 predict orthology (out of a score of 16) (Hu *et al.*, 2011). Fly stocks were obtained from  
548 Vienna *Drosophila* Resource Center (VDRC) and Bloomington *Drosophila* Stock Center  
549 (BDSC). Lines include *Hand<sup>4.2</sup>-Gal4* (Han *et al.*, 2006), *tdtK* (Klassen *et al.*, 2017), *tinCΔ4-*  
550 *Gal4* (Lo and Frasch, 2001), *Dot-Gal4* (Kimbrell *et al.*, 2002), *Mef2-Gal4* (Ranganayakulu  
551 *et al.*, 2010), Mito::GFP (BDSC: 8442), *CHCHD<sup>DefA</sup>* (BL: 26847), *CHCHD3/6 A* (VDRC:  
552 52251), *CHCHD3/6 B* (VDRC: 105329), *CHCHD3/6 C* (BDSC: 51157), *CHCHD3/6 D*  
553 (BDSC: 38984), DUOX (BDSC: 32903), Mitofilin A (VDRC: 47615), Mitofilin B (VDRC:  
554 106757), Mic13 A (VDRC: 14283), Mic13 B (VDRC: 100911), Mic10 A (VDRC: 102479),  
555 APOO(L) A (VDRC: 31098), Sam50 A (VDRC: 33641), Sam50 B (VDRC: 33642)  
556 *CHCHD<sup>D1</sup>* was kindly shared by the Ge lab (Deng *et al.*, 2016).

557 Assessment of lethality in co-KD of *CHCHD3/6* and *Cdk12* refers to percentage of  
558 surviving flies at 1 week-of-age, versus the number of flies eclosed on day 0.

### 559 ***In situ* heartbeat analysis**

560 An *in-situ* dissection approach was used to expose the denervated beating fly heart  
561 (Martin Fink *et al.*, 2009; Ocorr *et al.*, 2009; Vogler and Ocorr, 2009). SOHA (Semi-  
562 automated optical heartbeat analysis) was used to analyze high speed video recordings  
563 to determine heart-related parameters (Martin Fink *et al.*, 2009). Flies (n>15) were briefly  
564 anesthetized using filter paper with 10µm FlyNap and transferred to a 10 X 35mm Petri  
565 dish with Vaseline to attach the hydrophobic wing cuticle to the dish. Oxygenated room  
566 temperature artificial hemolymph (108mM NaCl, 5mM KCl, 2mM CaCl<sub>2</sub>•2H<sub>2</sub>O, 8mM  
567 MgCl<sub>2</sub>•6H<sub>2</sub>O, 15mM pH 7.1 HEPES, 1mM NaH<sub>2</sub>PO<sub>4</sub>•H<sub>2</sub>O, 4mM NaHCO<sub>3</sub>, 10mM sucrose,  
568 and 5mM trehalose) was added to each dish. Flies were dissected as per (Vogler and  
569 Ocorr, 2009) and oxygenated for minimum 15 minutes to equilibrate. Dissected flies were

570 filmed for 30 seconds using an Olympus BX63 microscope (10X magnification), a  
571 Hamamatsu C11440 ORCA-flash4.0 OLT digital camera, and HCLmageLive program.  
572 These videos were uploaded to SOHA (semi-automated optical heartbeat analysis), end  
573 diastolic and end systolic diameters were manually marked towards end of ostia, and  
574 heart-related parameters were extracted (Fink *et al.*, 2009).

### 575 ***In vivo* heartbeat analysis**

576 Norland #61 optical glue was placed on a 22 X 50mm coverslip (one small drop  
577 for each fly). Flies (n>15) were briefly anesthetized using filter paper with 10 $\mu$ m FlyNap,  
578 transferred to coverslip on individual adhesive drops with the dorsal side facing the  
579 coverglass, and cured for 30 seconds using ultraviolet light. The coverslip was then  
580 placed on a 10 X 35mm Petri dish and secured using putty. Fly hearts were filmed for 5  
581 seconds using an Olympus BX63 microscope (20X magnification), a Hamamatsu C11440  
582 ORCA-flash4.0LT digital camera, and HCLmage Live program. All analysis was  
583 automatically processed using R (Vogler, 2021)([gvogler/FlyHearts-tdtK-Rscripts](#): First  
584 release of the R tdtK script. (Zenodo, 2021). doi:10.5281/zenodo.4749935.).

### 585 **Adult *Drosophila* heart immunohistochemistry**

586 Flies were dissected as per (Vogler and Ocorr, 2009) in a 10 X 35mm Petri dish  
587 and EGTA was added to a final concentration of 10mM. EGTA was removed and replaced  
588 with 4% methanol-free formaldehyde for 20 minutes. Formaldehyde was removed and  
589 replaced with 1X PBS 3 times. Flies thoraxes were removed, abdominal walls were  
590 trimmed, and excess fat around heart was removed. Hearts were then washed 3 times  
591 with 0.3% PBTx (Triton-X) for 15 minutes on a shaker. PBTx was removed and replaced  
592 with 200 $\mu$ L 1 $^{\circ}$  antibody solution (0.3% PBTx + 1 $^{\circ}$  antibody), then a small piece of Parafilm  
593 with carefully placed over the solution to form and seal of liquid over the hearts. Dishes  
594 were incubated either 1) at 4 $^{\circ}$ C overnight or 2) at room temperature for 2 hours while  
595 shaking. Once finished incubating, Parafilm was gently removed with forceps and 3 15-  
596 minute washes with 0.3% PBTx were performed. PBTx was removed and replaced with  
597 200 $\mu$ L 2 $^{\circ}$  antibody solution (0.3% PBTx + 2 $^{\circ}$  antibody), then a small piece of Parafilm was  
598 carefully placed over the solution. Dishes were incubated either 1) at 4 $^{\circ}$ C overnight or 2)

599 at room temperature for 2 hours while shaking. Parafilm was gently removed with forceps  
600 and 3 15-minute washes with 0.3% PBTx were performed. PBTx was removed and  
601 replaced with 1X PBS. Ventral cuticle with attached hearts were carefully removed  
602 individually from the Vaseline layer and transferred to a 25 X 75 X 1mm slide with 2 18 X  
603 18mm No. 1 coverslips glued to form a bridge and ProLong Gold antifade mounting  
604 medium (Invitrogen) in the middle. Flies were placed ventral side up and covered with a  
605 18 X 18mm No. 1.5 coverslip, sealed with clear nail polish around the edges, and stored  
606 at room temperature for 24 hours until being moved to 4°C.

607 Primary Antibodies: anti-dMef2 (1:20, gift from Dr. Bruce Paterson); anti-slit (1:40,  
608 c555 DSHB); anti-Myosin (1:50, 3E8-3D3 DSHB); anti-Sallimus (1:100, Abcam); anti-  
609 ATP5A (1:100, Abcam 14748); anti-ATP5A1 (1:200, Invitrogen 43-9800). All Secondaries  
610 from Jackson Immuno Research Labs used at 1:500: Goat anti-Rat 594; Goat anti-Rabbit  
611 647; Goat anti-Rabbit Cy5; Goat anti-mouse Cy3. Dyes: Phalloidin 594 or 647 (1:100,  
612 Invitrogen).

### 613 ***Drosophila* indirect flight muscle dissection and immunofluorescence**

614 Thoraxes were removed under light CO<sub>2</sub> pressure and fixed for 40 minutes in 5%  
615 PFA, followed by three 2-minute PBS washes. IFM muscle fibers were removed using  
616 fine (#55) forceps and washed with 0.5% PBTx for 15 minutes, then washed with 0.1%  
617 PBTx twice for 15 minutes. All subsequent antibody stainings were diluted in 0.1% PBTx  
618 and incubated shaking at 4°C overnight to penetrate the muscle tissue. IFMs were  
619 transferred to a 25 X 75 X 1mm slide without a bridge. ProLong Gold antifade mounting  
620 medium (Invitrogen) was added, the samples were covered with a 18 X 18mm No. 1.5  
621 coverslip, and sealed with clear nail polish around the edges.

### 622 ***Drosophila* embryo collection, fixation, and immunofluorescence**

623 Adult flies were reared in a plastic bottle cage with a Petri dish on the bottom  
624 containing grape agar (Agar, EtOH, glacial acetic acid, grape juice) and yeast paste  
625 (yeast and H<sub>2</sub>O) at 25°C. After incubating (16 hours), embryos were carefully collected  
626 with a brush and placed in a mesh basket. Flies were washed with water, then placed in  
627 bleach for 3 minutes, followed by 30 seconds of wash with water. Embryos were removed



628 from mesh and placed in a fixation solution (2 Heptane: 1 2X PBS: 1 10% formaldehyde)  
629 for 25 minutes. Formaldehyde layer (bottom) was removed, replaced with 500 $\mu$ L MetOH,  
630 vortexed, then the supernatant with vitelline membranes (middle layer) was removed, this  
631 was repeated once more. Embryos were washed with MetOH (3 rinses, followed by 1  
632 hour on rotator). Embryos were stored in fresh MetOH at -20°C. 1<sup>o</sup> antibody was added  
633 and tube was placed on rotator at 4°C overnight. 1<sup>o</sup> was later removed using 3X15 minute  
634 0.4% PBTx washes. PBTx was removed, replaced with 2<sup>o</sup> antibody (diluted in PBTx), and  
635 rotated for 2 hours. 2<sup>o</sup> was later removed using 3X15 minute 0.4% PBTx washes, then  
636 left in PBS at 4°C. Since *CHCHD<sup>D1</sup>* and *CHCHD<sup>DefA</sup>* are both homozygous lethal at adult  
637 stages, each line was rebalanced over TM6b YFP (*CHCHD<sup>D1</sup>/TM6b YFP* and  
638 *CHCHD<sup>DefA</sup>/TM6b YFP*). The YFP lines (*CHCHD<sup>D1</sup>/TM6b YFP* and *CHCHD<sup>DefA</sup>/TM6b*  
639 *YFP*) were crossed out and embryos were selected against GFP to obtain only  
640 *CHCHD<sup>D1</sup>/CHCHD<sup>DefA</sup>* embryos.

#### 641 **Fixed sample imaging**

642 Samples were imaged at 10X, 25X, or 40X magnification using a Zeiss Apotome.1  
643 Imager Z1, a Hamamatsu C11440 ORCA-flash4.0 OLT digital camera, and Zeiss ZEN.  
644 In order to obtain higher resolution, confocal microscopy was performed for all  
645 immunohistochemistry experiments involving Mito::GFP and ATP synthase staining.

#### 646 **Climbing assay**

647 Flies were initially anesthetized using FlyNap, placed into 5 separate vials, and  
648 counted for a total at week 0 for Control C females= 178, Control C males= 125,  
649 CHCHD3/6 C females= 154, CHCHD3/6 C males= 112. Each week, flies were transferred  
650 using a funnel to a clean longer tube with no food and these tubes were placed in a  
651 Styrofoam cutout to hold the tubes for tapping. The vial holder was tapped down multiple  
652 times until flies were at the base of the vial and then left to record the percentage of flies  
653 which reached 10cm after 10 seconds. The vial holder was tapped down multiple time to  
654 achieve biological replicates= 4 and different batches of genotypes were examined for  
655 technical replicates= 5.

## 656 **Statistical analyses**

657 All statistical analyses were performed using GraphPad Prism version 8.0.1 for  
658 Windows, GraphPad Software, San Diego, California USA, [www.graphpad.com](http://www.graphpad.com).  
659 Statistical tests used are stated in figure legends. T-tests were performed on most heart  
660 assays where only one variable was defined. For tdtK analyses, a ranked one-way  
661 ANOVA Kruskal–Wallis test was used. Combinatorial KD assays with MICOS subunits  
662 and *CHCHD3/6* loss-of-function in *Drosophila* were analyzed with two-way ANOVA.

## 663 **PCR**

664 The *CHCHD<sup>D1</sup>* line was confirmed via PCR using primers CHCHDD1 F4:  
665 ATATATCCGACGATGTGG and CHCHDD1 R4: AGCTCCTGGTTCATCTGG (Q5®  
666 High-Fidelity 2X Master Mix New England Bio).

## 667 **Quantitative real time polymerase chain reaction (qRT-PCR)**

668 RNA was extracted using Qiagen miRNeasy® Mini Kit and cDNA was synthesized  
669 with Qiagen QuantiTech® reverse transcription kit. qRT-PCR analysis was performed  
670 using Roche FastStart Essential DNA Probes Master and Roche LightCycler® 96 with 2  
671 biological replicates and 3 technical replicates. Data was analyzed in the LightCycler®  
672 application. Primers include *CHCHD3/6* F: GCTAGAGGAACTTCAAAGATGG,  
673 *CHCHD3/6* R: GGGATAGGAGGATACTTTCGG, *RP49* F:  
674 GCTAAGCTGTCGCACAAATG, *RP49* R: GTTCGATCCGTAACCGATGT.

## 675 **Human iPSC-derived cardiomyocyte proliferation assays**

676 At day 25 of differentiation, human iPSC-derived cardiomyocytes (hiPSC-CMs)  
677 were dissociated with TrypLE Select 10X (Gibco) for up to 12 min and action of TrypLE  
678 was neutralized with RPMI supplemented with 10% FBS. Cells were resuspended in  
679 RPMI with 2% KOSR (Gibco) and 2% B27 50X with vitamin A (Life Technologies)  
680 supplemented with 2 µM Thiazovivin and plated at a density of 5.000 cells per well in a  
681 Matrigel-coated 384-well plate. hiPSC-CMs were then transfected with siRNA  
682 (Dharmacon) directed against each gene using lipofectamine RNAi Max (ThermoFisher).

683 Each siRNA was tested in quadruplicate. 48 hours post-transfection, cells were labeled  
684 with 10  $\mu$ M EdU (ThermoFisher). After 24h of EdU incubation, cells were fixed with 4%  
685 paraformaldehyde for 30 minutes. EdU was detected according to the protocol and cells  
686 were stained with cardiac specific marker ACTN2 (Sigma A7811, dilution 1:800) and  
687 DAPI. Cells were imaged with ImageXpress Micro XLS microscope (Molecular Devices)  
688 and custom algorithms were used to quantify EdU+ hiPSC-CMs.

## 689 **ATP Measurements**

690 Measurements of ATP were performed using a luciferase assay as described  
691 previously (Liu and Lu, 2010; Zanon *et al.*, 2017). 10-12 hearts per sample were collected  
692 from 1-week old flies and homogenized in 100 $\mu$ l extraction buffer (100 mM Tris and 4 mM  
693 EDTA, pH 7.8) containing 6M guanidine-HCl followed by rapid freezing in liquid nitrogen.  
694 The samples were boiled for 5min and cleared by centrifugation at 14,000 x g.  
695 Supernatants were diluted 1:50 and ATP levels were determined using ENLITEN® ATP  
696 Assay System (Promega, Cat #FF2000) as per manufacturer instructions. Total protein  
697 levels were determined by BCA method (Pierce, Cat #23225). ATP measurements were  
698 normalized to protein.

## 699 **Hybridization Chain Reaction (HCR)**

700 Hearts were exposed as described above and RNA in situ performed and analyzed  
701 as described in (Kirkland *et al.*, 2021). Briefly, hearts were relaxed using 10mM EGTA in  
702 artificial hemolymph and fixed in 4% formaldehyde in 0.1% Tween 20-PBS for 20 minutes.  
703 Hearts were then washed with 0.1% Tween 20, PBS, 2 x 5 minutes. On ice, hearts were  
704 incubated in a methanol gradient with PBS for 5 minutes each (25%, 50%, 75%, 100%,  
705 75%, 50%, 25%). Hearts were then permeabilized in 1% Triton 100-X in PBS for 2 hours  
706 at room temperature. The hearts were post-fixed with 4% formaldehyde in 0.1% Tween  
707 20-PBS for 20 minutes at room temperature before washing on ice with 0.1% Tween 20-  
708 PBS, 2 x 5 minutes. Subsequently, samples were washed with 50% 0.1% Tween 20-PBS  
709 and 50% 5XSSCT (5X SSC, 0.1% Tween 20, H<sub>2</sub>O) for 5 minutes on ice, followed by 5X  
710 SSCT for another 5 minutes. The hearts were then transferred to a 96 well plate and the  
711 hearts incubated in probe hybridization buffer (Molecular Instruments) for 5 minutes on

712 ice, then 30 minutes at 37°C. The solution was then replaced with 2µl of each probe in  
713 200µl of probe hybridization buffer and incubated at 37°C overnight (up to 16 hours).  
714 Next, 4 x 15 minute washes were performed with probe wash buffer (Molecular  
715 Instruments) at 37° C, then 2 x 5 minute 5XSSCT and 1 x 5 minute amplification buffer  
716 (Molecular Instruments). 2µl of corresponding h1 and h2 hairpins (Molecular Instruments)  
717 were heated to 95°C for 90 seconds, cooled in the dark for 30 minutes and added to 100µl  
718 of amplification buffer. Hairpin solution was then incubated with the heart samples at room  
719 temperature overnight (up to 16 hours), in the dark. Next, samples were washed 2 x 5  
720 minutes with 5X SSCT; 2 x 30 minutes with 5X SSCT; 1 x 5 minutes with 5X SSCT and  
721 rinsed 3 x with PBS. DAPI in PBS (1:500) was incubated with the samples for 15 minutes,  
722 then samples were again rinsed 3 x 5 minutes in PBS. Samples were then mounted and  
723 imaged as described above. To quantify expression, a maximum projection image was  
724 created in ImageJ from the confocal stack image and binarized. The region around the  
725 cardiomyocyte nucleus was traced and the ROI copied to the binary image for particle  
726 analysis. Since segmentation was imperfect for transcripts very close together and to  
727 account for differences in pocket size, the % area covered by the transcripts was used to  
728 assess statistical significance in Prism (Graphpad).

729

730

731

732 **REFERENCES**

- 733 Ackermann, A. and Brieger, A. (2019) 'The Role of Nonerythroid Spectrin  $\alpha$ II in Cancer',  
734 *Journal of Oncology*, 2019, pp. 1–14. doi: 10.1155/2019/7079604.
- 735 Ahmad, S. M. (2017) 'Conserved signaling mechanisms in Drosophila heart  
736 development', *Developmental Dynamics*. John Wiley & Sons, Ltd, 246(9), pp. 641–656.  
737 doi: <https://doi.org/10.1002/dvdy.24530>.
- 738 Alston, C. L. *et al.* (2017) 'The genetics and pathology of mitochondrial disease', *Journal*  
739 *of Pathology*, pp. 236–250.
- 740 Altmann, K. *et al.* (2000) 'Two-Dimensional Echocardiographic Assessment of Right  
741 Ventricular Function as a Predictor of Outcome in Hypoplastic Left Heart Syndrome',  
742 *The American Journal of Cardiology*, 86, pp. 964–968.
- 743 Bartkowiak, B. *et al.* (2010) 'CDK12 is a transcription elongation-associated CTD  
744 kinase, the metazoan ortholog of yeast Ctk1', *Genes and Development*, 24(20), pp.  
745 2303–2316. doi: 10.1101/gad.1968210.
- 746 Benson, G. (1999) 'Tandem repeats finder: a program to analyze DNA sequences',  
747 *Nucleic acids research*, 27(2), pp. 573–580. doi: 10.1093/nar/27.2.573.
- 748 Bhandari, P., Song, M. and Dorn, G. W. (2015) 'Dissociation of mitochondrial from  
749 sarcoplasmic reticular stress in Drosophila cardiomyopathy induced by molecularly  
750 distinct mitochondrial fusion defects', *Journal of molecular and cellular cardiology*.  
751 2014/12/30, 80(2), pp. 71–80. doi: 10.1016/j.yjmcc.2014.12.018.
- 752 Bier, E. and Bodmer, R. (2004) 'Drosophila, an emerging model for cardiac disease',  
753 *Gene*, 342(1), pp. 1–11. doi: 10.1016/j.gene.2004.07.018.
- 754 Bodmer, R. (1995) 'Heart Development in Drosophila and its Relationship to  
755 Vertebrates', *Trends Cardiovasc Med.*, 1738(94), pp. 21–28.
- 756 Bodmer, R. and Frasch, M. (2010) *Development and Aging of the Drosophila Heart*,  
757 *Heart Development and Regeneration*. Elsevier Inc.
- 758 Brand, A. H. and Perrimon, N. (1993) 'Targeted gene expression as a means of altering  
759 cell fates and generating dominant phenotypes', *Development*. 1993/06/01, 118(2), pp.

- 760 401–415.
- 761 Carlier, M. (1998) ‘Control of actin dynamics’, *Current Opinion in Cell Biology*, 132, pp.  
762 45–51.
- 763 Carlier, M. F., Pantaloni, D. and Korn, E. D. (1984) ‘Evidence for an ATP cap at the  
764 ends of actin filaments and its regulation of the F-actin steady state’, *Journal of*  
765 *Biological Chemistry*, 259(16), pp. 9983–9986. doi: 10.1016/s0021-9258(18)90914-2.
- 766 Cogliati, S., Enriquez, J. A. and Scorrano, L. (2016) ‘Mitochondrial Cristae: Where  
767 Beauty Meets Functionality’, *Trends in Biochemical Sciences*. Elsevier Ltd, 41(3), pp.  
768 261–273. doi: 10.1016/j.tibs.2016.01.001.
- 769 Cripps, R. M. and Olson, E. N. (2002) ‘Control of Cardiac Development by an  
770 Evolutionarily Conserved Transcriptional Network’, *Developmental Biology*, 28, pp. 14–  
771 28. doi: 10.1006/dbio.2002.0666.
- 772 Crucean, A. *et al.* (2017) ‘Re-evaluation of hypoplastic left heart syndrome from a  
773 developmental and morphological perspective’, *Orphanet Journal of Rare Diseases*.  
774 *Orphanet Journal of Rare Diseases*, 12(1), pp. 1–10. doi: 10.1186/s13023-017-0683-4.
- 775 Darshi, M. *et al.* (2011) ‘ChChd3, an inner mitochondrial membrane protein, is essential  
776 for maintaining Crista integrity and mitochondrial function’, *Journal of Biological*  
777 *Chemistry*, 286(4), pp. 2918–2932. doi: 10.1074/jbc.M110.171975.
- 778 Deng, Q. *et al.* (2016) ‘Cross-talk between mitochondrial fusion and the Hippo pathway  
779 in controlling cell proliferation during *Drosophila* development’, *Genetics*, 203(4), pp.  
780 1777–1788. doi: 10.1534/genetics.115.186445.
- 781 Ding, C. *et al.* (2015) ‘Mitofilin and CHCHD6 physically interact with Sam50 to sustain  
782 cristae structure’, *Scientific Reports*. Nature Publishing Group, 5, pp. 1–11. doi:  
783 10.1038/srep16064.
- 784 Fink, Martin *et al.* (2009) ‘A new method for detection and quantification of heartbeat  
785 parameters in *Drosophila*, zebrafish, and embryonic mouse hearts’, 46(2), pp. 101–113.  
786 doi: 10.2144/000113078.A.
- 787 Fink, M *et al.* (2009) ‘A new method for detection and quantification of heartbeat



- 788 parameters in *Drosophila*, zebrafish, and embryonic mouse hearts', *Biotechniques*.  
789 2009/03/26, 46(2), pp. 101–113. doi: 10.2144/000113078.
- 790 Friedman, J. R. *et al.* (2015) 'MICOS coordinates with respiratory complexes and lipids  
791 to establish mitochondrial inner membrane architecture', *eLife*. Edited by R. J. Youle.  
792 eLife Sciences Publications, Ltd, 4, p. e07739. doi: 10.7554/eLife.07739.
- 793 Gaber, N. *et al.* (2013) 'Fetal Reprogramming and Senescence in Hypoplastic Left  
794 Heart Syndrome and in Human Pluripotent Stem Cells during Cardiac Differentiation',  
795 *The American Journal of Pathology*. Elsevier, 183(3), pp. 720–734. doi:  
796 10.1016/j.ajpath.2013.05.022.
- 797 Garg, V. *et al.* (2005) 'Mutations in NOTCH1 cause aortic valve disease', *Nature*,  
798 437(September), pp. 1–5. doi: 10.1038/nature03940.
- 799 Goldberg, D. J. and Rychik, J. (2016) 'Hypoplastic Left Heart Syndrome', in  
800 *Echocardiography in Pediatric and Congenital Heart Disease: From Fetus to Adult:*  
801 *Second Edition*, pp. 357–381. doi: 10.1002/9781118742440.ch20.
- 802 Grossfeld, P. *et al.* (2019) 'Hypoplastic Left Heart Syndrome: A New Paradigm for an  
803 Old Disease?', *Journal of Cardiovascular Development and Disease*, 6(1), pp. 1–13.  
804 doi: 10.3390/jcdd6010010.
- 805 Han, Z. *et al.* (2006) 'Hand, an evolutionarily conserved bHLH transcription factor  
806 required for *Drosophila* cardiogenesis and hematopoiesis', *DEVELOPMENT AND*  
807 *DISEASE*, 1182, pp. 1175–1182. doi: 10.1242/dev.02285.
- 808 Han, Z. and Olson, E. N. (2005) 'Hand is a direct target of Tinman and GATA factors  
809 during *Drosophila* cardiogenesis and hematopoiesis', *Development*, 132(15), pp. 3525–  
810 3536. doi: 10.1242/dev.01899.
- 811 Hu, Y. *et al.* (2011) 'An integrative approach to ortholog prediction for disease-focused  
812 and other functional studies', *BMC Bioinformatics*, 12(357), pp. 1–16. doi:  
813 10.1186/1471-2105-12-357.
- 814 Jin, S. C. *et al.* (2017) 'Contribution of rare inherited and de novo variants in 2,871  
815 congenital heart disease probands', *Nature Genetics*, 49(11), pp. 1593–1601. doi:  
816 10.1038/ng.3970.

- 817 Karczewski, K. J. *et al.* (2020) 'The mutational constraint spectrum quantified from  
818 variation in 141,456 humans', *Nature*, 581(7809), pp. 434–443. doi: 10.1038/s41586-  
819 020-2308-7.
- 820 Kimbrell, D. A. *et al.* (2002) 'The Dorothy Enhancer Has Tinman Binding Sites and  
821 Drives hopscotch -Induced Tumor Formation', 28, pp. 23–28. doi: 10.1002/gene.10134.
- 822 Kirkland, N. *et al.* (2021) 'Age-dependent Lamin remodeling induces cardiac dysfunction  
823 via dysregulation of cardiac transcriptional programs'. Available at:  
824 <https://doi.org/10.21203/rs.3.rs-1021378/v1>.
- 825 Klassen, M. P. *et al.* (2017) 'Age-dependent diastolic heart failure in an in vivo  
826 *Drosophila* model', *eLife*, 6, pp. 1–22. doi: 10.7554/eLife.20851.
- 827 Kobayashi, J. *et al.* (2014) 'Directed Differentiation of Patient-Specific Induced  
828 Pluripotent Stem Cells Identifies the Transcriptional Repression and Epigenetic  
829 Modification of NKX2-5, HAND1, and NOTCH1 in Hypoplastic Left Heart Syndrome',  
830 *PLoS ONE*, 9(7), pp. 1–14. doi: 10.1371/journal.pone.0102796.
- 831 Korn, E. D., Carlier, M. F. and Pantaloni, D. (1987) 'Actin polymerization and ATP  
832 hydrolysis', *Science*, 238(4827), pp. 638–644. doi: 10.1126/science.3672117.
- 833 Kozjak-Pavlovic, V. (2017) 'The MICOS complex of human mitochondria', *Cell and  
834 Tissue Research*. Cell and Tissue Research, pp. 83–93. doi: 10.1007/s00441-016-  
835 2433-7.
- 836 Li, H. *et al.* (2016) 'Mic60/Mitofilin determines MICOS assembly essential for  
837 mitochondrial dynamics and mtDNA nucleoid organization', *Cell Death and  
838 Differentiation*, 23(3), pp. 380–392. doi: 10.1038/cdd.2015.102.
- 839 Liu, S. and Lu, B. (2010) 'Reduction of Protein Translation and Activation of Autophagy  
840 Protect against PINK1 Pathogenesis in *Drosophila melanogaster*', *PLOS Genetics*.  
841 Public Library of Science, 6(12), p. e1001237. Available at:  
842 <https://doi.org/10.1371/journal.pgen.1001237>.
- 843 Liu, X. *et al.* (2017) 'The complex genetics of hypoplastic left heart syndrome', *Nat  
844 Genet.*, 49(7), pp. 1152–1159. doi: 10.1038/ng.3870.The.

- 845 Lo, P. C. H. and Frasch, M. (2001) 'A role for the COUP-TF-related gene seven-up in  
846 the diversi® cation of cardioblast identities in the dorsal vessel of *Drosophila*', 104, pp.  
847 49–60.
- 848 Marian, A. J. and Belmont, J. (2011) 'Strategic approaches to unraveling genetic causes  
849 of cardiovascular diseases', *Circulation Research*, 108(10), pp. 1252–1269. doi:  
850 10.1161/CIRCRESAHA.110.236067.
- 851 Martínez-Morentin, L. *et al.* (2015) 'Cardiac deficiency of single cytochrome oxidase  
852 assembly factor scox induces p53-dependent apoptosis in a *Drosophila* cardiomyopathy  
853 model', *Human Molecular Genetics*, 24(13), pp. 3608–3622. doi: 10.1093/hmg/ddv106.
- 854 McBride, K. L. *et al.* (2008) 'NOTCH1 mutations in individuals with left ventricular  
855 outflow tract malformations reduce ligand-induced signaling', *Human Molecular*  
856 *Genetics*, 17(18), pp. 2886–2893. doi: 10.1093/hmg/ddn187.
- 857 McKenna, A. *et al.* (2010) 'The Genome Analysis Toolkit: a MapReduce framework for  
858 analyzing next-generation DNA sequencing data', *Genome research*. 2010/07/19. Cold  
859 Spring Harbor Laboratory Press, 20(9), pp. 1297–1303. doi: 10.1101/gr.107524.110.
- 860 Mussa, S. and Barron, D. J. (2017) 'Hypoplastic left heart syndrome', *Paediatrics and*  
861 *Child Health*, 27(2), pp. 75–82. doi: <https://doi.org/10.1016/j.paed.2016.12.002>.
- 862 Ocorr, K. *et al.* (2009) 'Semi-automated Optical Heartbeat Analysis of small hearts',  
863 *Journal of visualized experiments : JoVE*. MyJove Corporation, (31), p. 1435. doi:  
864 10.3791/1435.
- 865 Ott, C. *et al.* (2012) 'Sam50 functions in mitochondrial intermembrane space bridging  
866 and biogenesis of respiratory complexes.', *Molecular and cellular biology*, 32(6), pp.  
867 1173–1188. doi: 10.1128/MCB.06388-11.
- 868 Paige, S. *et al.* (2020) 'Patient-specific induced pluripotent stem cells implicate intrinsic  
869 impaired contractility in hypoplastic left heart syndrome', *Circulation*, pp. 1605–1608.
- 870 Palikaras, K., Lionaki, E. and Tavernarakis, N. (2015) 'Coupling mitogenesis and  
871 mitophagy for longevity', *Autophagy*, 11(8), pp. 1428–1430. doi:  
872 10.1080/15548627.2015.1061172.

- 873 Palikaras, K. and Tavernarakis, N. (2014) 'Mitochondrial homeostasis: The interplay  
874 between mitophagy and mitochondrial biogenesis', *Experimental Gerontology*. Elsevier  
875 Inc., 56, pp. 182–188. doi: 10.1016/j.exger.2014.01.021.
- 876 Pandey, U. B. and Nichols, C. D. (2011) 'Human Disease Models in *Drosophila*  
877 melanogaster and the Role of the Fly in Therapeutic Drug Discovery', *Drug Delivery*,  
878 63(2), pp. 411–436. doi: 10.1124/pr.110.003293.411.
- 879 Poplin, R. *et al.* (2018) 'Scaling accurate genetic variant discovery to tens of thousands  
880 of samples', *bioRxiv*, p. 201178. doi: 10.1101/201178.
- 881 Raney, B. J. *et al.* (2014) 'Track data hubs enable visualization of user-defined genome-  
882 wide annotations on the UCSC Genome Browser', *Bioinformatics (Oxford, England)*.  
883 2013/11/13. Oxford University Press, 30(7), pp. 1003–1005. doi:  
884 10.1093/bioinformatics/btt637.
- 885 Ranganayakulu, G. *et al.* (2010) 'Divergent roles for NK-2 class homeobox genes in  
886 cardiogenesis in flies and mice', 3048(1998), pp. 3037–3048.
- 887 Romanello, V. and Sandri, M. (2016) 'Mitochondrial quality control and muscle mass  
888 maintenance', *Frontiers in Physiology*, pp. 1–21.
- 889 Sun, N., Youle, R. J. and Finkel, T. (2016) 'The Mitochondrial Basis of Aging', *Molecular*  
890 *cell*, 61(5), pp. 654–666. doi: 10.1016/j.molcel.2016.01.028.
- 891 Tang, J. *et al.* (2020) 'Sam50–Mic19–Mic60 axis determines mitochondrial cristae  
892 architecture by mediating mitochondrial outer and inner membrane contact', *Cell Death*  
893 *and Differentiation*. Springer US, 27(1), pp. 146–160. doi: 10.1038/s41418-019-0345-2.
- 894 Tchervenkov, C. I. *et al.* (2006) 'The nomenclature, definition and classification of  
895 hypoplastic left heart syndrome', *Cardiology in the Young*, 16(4), pp. 339–368. doi:  
896 10.1017/S1047951106000291.
- 897 Theis, J. L., Hrstka, S. C. L., *et al.* (2015) 'Compound heterozygous NOTCH1 mutations  
898 underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome',  
899 *Human Genetics*. Springer Berlin Heidelberg, 134(9), pp. 1003–1011. doi:  
900 10.1007/s00439-015-1582-1.

- 901 Theis, J. L., Zimmermann, M. T., *et al.* (2015) 'Recessive MYH6 Mutations in  
902 Hypoplastic Left Heart With Reduced Ejection Fraction.', *Circulation. Cardiovascular*  
903 *genetics*. United States, 8(4), pp. 564–571. doi: 10.1161/CIRCGENETICS.115.001070.
- 904 Theis, J. L. *et al.* (2020) 'Patient-specific genomics and cross-species functional  
905 analysis implicate LRP2 in hypoplastic left heart syndrome', *eLife*. Edited by D. Y. R.  
906 Stainier, A. Ebert, and L. Kochilas. eLife Sciences Publications, Ltd, 9, p. e59554. doi:  
907 10.7554/eLife.59554.
- 908 Theis, J. L. *et al.* (2021) 'Genetic Association Between Hypoplastic Left Heart Syndrome  
909 and Cardiomyopathies', *Circulation: Genomic and Precision Medicine*. American Heart  
910 Association, 14(1), p. e003126. doi: 10.1161/CIRCGEN.120.003126.
- 911 Theis, J. L. *et al.* (2022) 'CELSR1 Risk Alleles in Familial Bicuspid Aortic Valve and  
912 Hypoplastic Left Heart Syndrome', *Circulation: Genomic and Precision Medicine*.  
913 American Heart Association, 15(2), p. e003523. doi: 10.1161/CIRCGEN.121.003523.
- 914 Theis, J. L. and Olson, T. M. (2022) 'Whole Genome Sequencing in Hypoplastic Left  
915 Heart Syndrome', *Journal of Cardiovascular Development and Disease*. doi:  
916 10.3390/jcdd9040117.
- 917 Tocchi, A. *et al.* (2015) 'Mitochondrial dysfunction in cardiac aging', *Biochimica et*  
918 *Biophysica Acta - Bioenergetics*. Elsevier B.V., 1847(11), pp. 1424–1433. doi:  
919 10.1016/j.bbabi.2015.07.009.
- 920 Tomita-mitchell, A. *et al.* (2016) 'Impact of MYH6 variants in hypoplastic left heart  
921 syndrome', *Physiological Genomics*. American Physiological Society, 48(12), pp. 912–  
922 921. doi: 10.1152/physiolgenomics.00091.2016.
- 923 Ugur, B., Chen, K. and Bellen, H. J. (2016) 'Drosophila tools and assays for the study of  
924 human diseases', *DMM Disease Models and Mechanisms*, 9(3), pp. 235–244. doi:  
925 10.1242/dmm.023762.
- 926 Vogler, G. (2021) 'gvogler/FlyHearts-tdtK-Rscripts: First release of the R tdtK script.'  
927 Zenodo. doi: 10.5281/zenodo.4749935.
- 928 Vogler, G. *et al.* (2021) 'Single-cell sequencing of the &lt;em>Drosophila</em>  
929 embryonic heart and muscle cells during differentiation and maturation', *bioRxiv*, p.

- 930 2021.01.15.426556. doi: 10.1101/2021.01.15.426556.
- 931 Vogler, G. and Ocorr, K. (2009) 'Visualizing the beating heart in *Drosophila*', *Journal of*  
932 *visualized experiments : JoVE*. MyJove Corporation, (31), p. 1425. doi: 10.3791/1425.
- 933 Xie, H. B. *et al.* (2013) 'The NADPH Metabolic Network Regulates Human a B- crystallin  
934 Cardiomyopathy and Reductive Stress in *Drosophila melanogaster*', 9(6). doi:  
935 10.1371/journal.pgen.1003544.
- 936 Xu, X. *et al.* (1998) 'Smad proteins act in combination with synergistic and antagonistic  
937 regulators to target Dpp responses to the *Drosophila* mesoderm', *Genes and*  
938 *Development*, 12(15), pp. 2354–2370. doi: 10.1101/gad.12.15.2354.
- 939 Yagi, H. *et al.* (2018) 'The Genetic Landscape of Hypoplastic Left Heart Syndrome',  
940 *Pediatric cardiology*. United States: Springer US, 39(6), pp. 1069–1081. doi:  
941 10.1007/s00246-018-1861-4.
- 942 Yamazaki, Y. *et al.* (2013) 'Goliath family E3 ligases regulate the recycling endosome  
943 pathway via VAMP3 ubiquitylation', *EMBO Journal*, 32(4), pp. 524–537. doi:  
944 10.1038/emboj.2013.1.
- 945 Yang, C. *et al.* (2017) 'Induced pluripotent stem cell modelling of HLHS underlines the  
946 contribution of dysfunctional NOTCH signalling to impaired cardiogenesis', *Human*  
947 *Molecular Genetics*, 26(16), pp. 3031–3045. doi: 10.1093/hmg/ddx140.
- 948 Ye, M. *et al.* (2009) 'Deletion of ETS-1, a gene in the Jacobsen syndrome critical region,  
949 causes ventricular septal defects and abnormal ventricular morphology in mice', *Human*  
950 *Molecular Genetics*, 19(4), pp. 648–656. doi: 10.1093/hmg/ddp532.
- 951 Yin, Z., Xu, X. L. and Frasch, M. (1997) 'Regulation of the twist target gene tinman by  
952 modular cis-regulatory elements during early mesoderm development', *Development*,  
953 124(24), pp. 4971–4982. doi: 10.1242/dev.124.24.4971.
- 954 Zanon, A. *et al.* (2017) 'SLP-2 interacts with Parkin in mitochondria and prevents  
955 mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and  
956 *Drosophila*', *Human molecular genetics*. Institute for Biomedicine, Eurac Research,  
957 Affiliated Institute of the University of Lübeck, 39100 Bolzano, Italy., 26(13), pp. 2412–  
958 2425. doi: 10.1093/hmg/ddx132.



959 Zhang, J. *et al.* (2019) 'Cardiomyocyte-specific loss of RNA polymerase II subunit 5-  
960 mediating protein causes myocardial dysfunction and heart failure', *Cardiovascular*  
961 *Research*, 115(11), pp. 1617–1628. doi: 10.1093/cvr/cvy307.

962

963

964 **Figure legends**

965 **Figure 1: Prioritization of *CHCHD6* in HLHS proband and its *Drosophila* ortholog**  
966 ***CHCHD3/6*. A)** Pedigree of index family 11H. The family includes consanguineous  
967 parents (denoted by double horizontal lines) without cardiac defects, one son with HLHS  
968 (proband), and two siblings without cardiac defects. **B)** List of 9 candidate genes derived  
969 from proband 11H with corresponding *Drosophila* orthologs. Orthology based on DIOPT  
970 score. Conserved *Drosophila* candidate HLHS genes were knocked down individually in  
971 the *Drosophila* heart using the *Hand<sup>4.2</sup>-Gal4* driver. The functional phenotypes listed were  
972 significantly different relative to Control<sup>A</sup> or Control<sup>B</sup> and were measured in 1-week old  
973 female *Drosophila* hearts. **C)** Schematic of *Drosophila* highlighting the abdominal region  
974 which includes the heart tube and flanking pericardial cells, where the *Hand<sup>4.2</sup>-Gal4* driver  
975 is expressed. Image adapted from (Xie *et al.*, 2013). **D)** End-Diastolic diameter (EDD), **E)**  
976 End-systolic diameter (ESD), and **F)** fractional shortening (FS) from 1-week old female  
977 *Hand<sup>4.2</sup>-Gal4 >CHCHD3/6* flies.

978 **Supp. Figure 1: *CHCHD3/6* KD in the *Drosophila* heart causes reduced fractional**  
979 **shortening due to systolic dysfunction. A)** EDD, **B)** ESD and **C)** FS from 3-week old  
980 *Hand<sup>4.2</sup>>CHCHD3/6* female flies. Very low number of *Hand<sup>4.2</sup>>CHCHD3/6<sup>RNAiB</sup>* flies  
981 reaching 3 weeks-of-age indicates lethality possibly due to stronger KD of *CHCHD3/6*. **D-**  
982 **F)** 1-week old *Hand<sup>4.2</sup>-Gal4, tdtK>CHCHD3/6* female flies measured for **D)** EDD, **E)** ESD  
983 and **F)** FS. **G)** Confocal images of *CHCHD3/6* mRNA and *tinman* mRNA (top) and  
984 processed images (bottom) using a custom ImageJ macro. **H-I)** *CHCHD3/6* and *tinman*  
985 mRNA in 1-week old female *Drosophila* hearts. **H)** *CHCHD3/6* mRNA relative to *tinman*  
986 mRNA is reduced in *Hand<sup>4.2</sup>>CHCHD3/6<sup>RNAiA</sup>* heart tissue. **I)** *tinman* mRNA % area, used  
987 as marker to normalize expression to. Fractional shortening in control and *CHCHD3/6* KD  
988 female flies at 3 weeks of age with a **J)** pericardial cell-specific driver (*DOT-Gal4*), **K)** all  
989 muscle cell specific driver (*Mef2-Gal4*), and **L)** neuronal driver (*elav-Gal4*). Note that  
990 *Mef2>CHCHD3/6<sup>RNAiA</sup>* was lethal at pupal stages. **M)** Fractional shortening  
991 measurements from *Hand<sup>4.2</sup>>DUOX<sup>RNAiC</sup>* 3-week old flies. Unpaired two-tailed t-test,  
992 \*p≤0.05, \*\*p≤0.01, \*\*\*p≤ 0.001, \*\*\*\*p≤ 0.0001; error bars represent SEM.

993 **Supplementary Table 1: Prioritized candidate genes from HLHS proband.** Nine  
994 candidate genes harbored rare homozygous variants predicted to impact protein structure  
995 or gene regulation. Chr = chromosome, CADD = combined annotation dependent  
996 depletion, Hom = homozygous, Het = heterozygous, WT = wildtype, gnomAD = Genome  
997 Aggregation Database, MAF = minor allele frequency.

998 **Figure 2: *CHCHD3/6* expression is important for adult cardiac function around**  
999 **larval stages and early adult stages. A)** UMAP (uniform manifold approximation and  
1000 projection) plot from CB-specific single-cell transcriptomics (Vogler *et al.*, 2021) showing  
1001 expression of *CHCHD3/6* in CBs, as identified by cardiac TFs *tin*, *H15*, and *Hand*. **B)**  
1002 Stage 16-17 embryos (late stage cardiogenesis) were collected from a *CHCHD3/6* loss  
1003 of function line (*CHCHD<sup>D1</sup>*) line crossed to a *CHCHD3/6* deficiency line (*CHCHD<sup>DefA</sup>*) and  
1004 stained for Mef2 (all muscle transcription factor, magenta) and Slit (secreted protein of  
1005 the lumen, green). 50µm scale. **C)** *tinD>Control<sup>A</sup>* or *>CHCHD3/6<sup>RNAiA</sup>* were reared at 29°C  
1006 and females were filmed and imaged at 1-week of age. **A)** *tinD>CHCHD3/6<sup>RNAiA</sup>* did not  
1007 have a significant reduction in fractional shortening compared to *tinD>Control<sup>A</sup>* flies. **D)**  
1008 F-actin was unchanged between *tinD>Control<sup>A</sup>* and *tinD>CHCHD3/6<sup>RNAiA</sup>* flies at 1 week  
1009 of age; 20µm scale. **E)** Schematic overview of temperature shift experiments. **F-I)**  
1010 Fractional shortening measurements from 1-week old female flies reared at **F)** 19°C for  
1011 whole life, **G)** at 29°C for whole life, **H)** 19°C, and moved to 29°C at early pupal stages,  
1012 or **I)** 19 °C, and moved to 29°C once eclosed (virgin flies), Unpaired two-tailed t-test,  
1013 \*\*\*\*p≤ 0.0001, error bars represent SEM.

1014 **Figure 3: Cardiac tissue from heart-specific *CHCHD3/6* KD flies exhibit reduced and**  
1015 **altered sarcomeric proteins in the myocardial tissue. A)** Schematic of sarcomeric  
1016 protein distribution inside myofibrils (image created with BioRender.com). **B)** F-actin  
1017 staining in 1-week old female *Drosophila* hearts with *Hand<sup>4.2</sup>-Gal4* KD of *CHCHD3/6*.  
1018 Arrowheads indicate ostial myofibrils and arrows point to myocardial myofibrils (non-  
1019 ostial). **C)** F-actin intensity measured as mean gray value (gray value/# of pixels) along  
1020 myocardial myofibrils relative to mean gray value of ostial myofibrils. **D)** Mean intensity of  
1021 F-actin along individual myofibrils. 1-week old *Drosophila* hearts with *Hand<sup>4.2</sup>-Gal4* driven  
1022 KD of control or *CHCHD3/6* stained for antibodies against **E)** Myosin, **F)** Obscurin, **G)** α-

1023 Actinin, or **H**) Sallimus. Arrowheads indicate ostial myofibrils and arrows point to working  
1024 cardiomyocyte tissue (non-ostial). **I-L**) Mean fluorescence intensity along myocardial  
1025 myofibrils relative to ostia myofibrils in 1-week old *Hand<sup>4.2</sup>-Gal4>CHCHD3/6<sup>RNAiA</sup>* adults  
1026 stained for sarcomeric proteins **I**) Myosin, **J**) Obscurin, **K**)  $\alpha$ -Actinin, or **L**) Sallimus.  
1027 Unpaired two-tailed t-test, \*\* $p \leq 0.01$ , \*\*\*\* $p \leq 0.0001$ ; error bars represent SEM. 20 $\mu$ m scale.

1028 **Supp. Figure 2: A-C**) Candidate genes involved in polymerization/de-polymerization of  
1029 F-actin phenotypes upon KD using a *Hand<sup>4.2</sup>-Gal4;tdtK<sup>attP2</sup>* driver, measured at 1-week of  
1030 age. **D**) Fractional shortening from RNAi<sup>A</sup> lines. **E**) F-actin phenotype of hits **C**). 20 $\mu$ m  
1031 scale. Unpaired two-tailed t-test, \* $p \leq 0.05$ , \*\* $p \leq 0.01$ ; error bars represent SEM. FS=  
1032 fractional shortening, DD= End diastolic diameter, SD= Systolic diameter.

1033 **Figure 4: Mitochondria are aggregated and show reduced Complex IV and V**  
1034 **staining upon loss of CHCHD3/6.** Visualization of F-actin and mitochondria in  
1035 *Drosophila* indirect flight muscles (IFMs). **A-E**) 1-2 day-old male *Drosophila* IFMs with  
1036 Mito::GFP; *Mef2-Gal4* stained for **A**) F-actin, **B**) GFP (Mito::GFP (GFP tagged COX8A)),  
1037 **C**) ATP synthase, **D**) merged image of B + C, and **E**) merged image of A + B, 10 $\mu$ m scale.  
1038 **F**) *Hand<sup>4.2</sup>>CHCHD3/6<sup>RNAiA</sup>* heart tissue at 1-week of age. **G-I**) F-actin and Mito::GFP  
1039 staining in 1-week old female hearts using the *Hand<sup>4.2</sup>-Gal4; Mito::GFP* driver, 20 $\mu$ m  
1040 scale. **J-L**) *Hand<sup>4.2</sup>-Gal4; tdtK* driven KD of ATP synthase subunits at 1-week of age  
1041 measuring **J**) diastolic diameter, **K**) systolic diameter, and **L**) fractional shortening. Data  
1042 is plotted as  $\pm$  SEM and significance indicated relative to Control<sup>GD2</sup>. \*\*\*\* $P \leq 0.0001$ ,  
1043 \*\* $P \leq 0.01$ . **M**) 1-week old *Hand<sup>4.2</sup>-Gal4; tdtK* driven KD of ATP synthase subunits with  
1044 altered F-actin (*CHCHD3/6* KD is depicted to contrast the structural phenotypes). **N**)  
1045 Quantification of ATP levels from hearts of 1-week old flies (10-12 hearts per sample).  
1046 ATP measurements were plotted relative to protein content. Statistical differences were  
1047 calculated by one-way ANOVA followed by Tukey's *post hoc* test for multiple  
1048 comparisons.

1049 **Supplementary Table 2: Mitochondrial gene screen in the *Drosophila* heart.** RNAi  
1050 lines of different mitochondrial functional groups were selected using the FlyBase.org  
1051 gene ontology (GO) term mitochondrion (GO:0005739). The RNAi lines were crossed to  
1052 *Hand<sup>4.2</sup>-Gal4, tdtK* and their progeny were assessed for contractility defects at 1-week of

1053 adult age using *Hand<sup>4.2</sup>-Gal4*; tdtK. Note that structural phenotype refers to any visible F-  
1054 actin phenotype, not specifically to *CHCHD3/6* KD F-actin phenotype. FS= fractional  
1055 shortening, DD= End diastolic diameter, SD= systolic diameter.

1056 **Supp. Figure 3: A)** KD of mitochondrial ATP synthase subunits using *Hand<sup>4.2</sup>-Gal4*; tdtK  
1057 produced strong F-actin phenotypes. 20µm scale. **B-C)** *CHCHD3/6* was knocked down  
1058 using a Mito::GFP; *Mef2-Gal4* line; note that Mito::GFP; *Mef2-Gal4*>*CHCHD3/6<sup>RNAiA</sup>* is  
1059 pupal lethal. **B)** Viability was significantly reduced in male and female *CHCHD3/6<sup>RNAiC1</sup>*  
1060 flies over a 4-week time course. Mantel-Cox test. **C)** Negative Geotaxis assay (average  
1061 number of flies above a 10cm mark after being tapped down in a long vial) measured in  
1062 1-week old male and female flies. Unpaired two-tailed t-test, \*\*\*\*p≤ 0.0001; error bars  
1063 represent SEM.

1064 **Figure 5: Assessment of other MICOS subunits in the *Drosophila* heart and in**  
1065 **VCMs. A)** Schematic of the MICOS complex and SAM50. Human MICOS subunits and  
1066 their respective *Drosophila* homologs are listed (image created with BioRender.com). **B)**  
1067 fractional shortening measured from 1-week old female flies with KD of individual MICOS  
1068 subunits and *Sam50* using a *Hand<sup>4.2</sup>-Gal4* driver. Unpaired two-tailed t-test, \*\*\*p≤ 0.001,  
1069 \*\*\*\*p≤ 0.0001; error bars represent SEM. **C)** *Hand<sup>4.2</sup>-Gal4*, tdtK; *CHCHD<sup>D1/+</sup>* line was  
1070 crossed out with Control<sup>A</sup>. Unpaired two-tailed t-test, error bars represent SEM. **D)** 1-  
1071 week old F-actin stained *Drosophila* hearts with or without heterozygous loss-of-function  
1072 *CHCHD<sup>D1/+</sup>* in the background, 20µm scale.

1073 **Supp. Figure 4: A)** End-Diastolic diameter and **B)** End-systolic diameter measured from  
1074 1-week old female flies with KD of individual MICOS subunits and *Sam50* using a *Hand<sup>4.2</sup>-*  
1075 *Gal4* driver. **C)** F-actin cardiac sarcomere staining in 1-week old female flies with *Hand<sup>4.2</sup>-*  
1076 *Gal4* KD. **D)** All MICOS subunits and *Sam50* were knocked down with *Hand<sup>4.2</sup>-Gal4*, tdtK  
1077 (filled squares) or using the sensitizer line *Hand<sup>4.2</sup>-Gal4*, tdtK; *CHCHD<sup>D1/+</sup>* (empty  
1078 squares) at 25°C. Two-way ANOVA with Tukey's multiple comparisons test, only  
1079 statistical comparisons between same RNAi lines are shown; error bars represent SEM,  
1080 20µm scale.

1081 **Supp. Figure 5: A, B)** Cardiac cell proliferation assay following MICOS complex subunit  
1082 KD, individually and in combination using EdU (proliferation marker, green) and ACTN1  
1083 (cardiac-specific, red) in ventricle-like cardiomyocytes (VCMs). **A)** VCMs showing  
1084 reduced proliferation with si*CHCHD6*. **B)** Quantification of proliferation between siRNA  
1085 mediated KD of individual MICOS subunits and MICOS subunit combination KDs in VCMs  
1086 (siTP53 is a positive control). One-way ANOVA with Dunnett's multiple comparisons test,  
1087 \* $p \leq 0.05$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ ; error bars represent standard deviation. One-way  
1088 ANOVA with Dunnett's multiple comparisons test, \* $p \leq 0.05$ , \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ ;  
1089 error bars represent standard deviation.



1090 **Supplementary Table 3: CHCHD3 and CHCHD6 MICOS variants in HLHS probands.**  
1091 Rare, predicted-damaging variants in CHCHD3 and CHCHD6 were identified in 6 of 183  
1092 HLHS probands in the Mayo Clinic cohort and the Pediatric Cardiac Genomics  
1093 Consortium (PCGC). Transcript and relevant protein variants are listed. Corresponding  
1094 *Drosophila* orthologs and orthology scores (DIOPT) are additionally listed (Hu *et al.*,  
1095 2011). Note that probands 87H and 363H both harbor *APOO* and *SAM50* variants.

1096 **Figure 6: HLHS CHCHD3 and CHCHD6 family-based gene interaction screen**  
1097 **reveals three hits. A)** A *Hand<sup>4.2</sup>-Gal4*, tdtK; CHCHD3/6<sup>RNAiC1</sup> sensitizer line show  
1098 reduced fractional shortening at 25°C, which is no longer significant at 21°C. Unpaired  
1099 two-tailed t-test, \*\*\*\* $p \leq 0.0001$ ; error bars represent SEM. **B)** Genetic interaction of  
1100 CHCHD3/6 and prioritized HLHS candidates. Two-way ANOVA with Tukey's multiple  
1101 comparisons test, only statistical comparisons between the same RNAi lines are shown;  
1102 \*\*\* $p \leq 0.001$ , \*\*\*\* $p \leq 0.0001$ ; error bars represent SEM. **C)** Functional overview of human  
1103 and *Drosophila* orthologs. KD of *Ckd12* with CHCHD3/6 KD led to increased lethality of  
1104 eclosed flies by 1 week-of-age.

1105 **Supplementary Table 4: Candidate genes from HLHS probands harboring CHCHD3**  
1106 **or CHCHD6 variants.** The majority of HLHS candidate genes has a *Drosophila* ortholog  
1107 (genes without ortholog highlighted in green).






# F. 1




**B**

Human Gene	Fly Gene	DIOPT	Fly phenotype when knocked down ( <i>Hand<sup>4.2</sup></i> )
RHBDL2	rho-4	6	∅
CAP1	capt	14	Constricted, ↓ Cardiac output
SZT2	No fly ortholog		
RNF149	gol	7	∅
CHCHD6	CHCHD3/6	6	↓↓ Contractility
MTRR	CG14882	8	∅
MBTPS1	S1P	14	∅
DGKE	Dgkepsilon	13	Arrhythmic, Dilated
C17orf67	No fly ortholog		




# S. F. 1




# T. 1

Gene symbol	Chr	BP Position (HG38)	Transcript variant	Gene Region	Protein variant	rsID	RegulomeDB Rank for Regulatory Variants	CADD Score for Missense Variants (Percentile)	Genotype in sister	Genotype in brother	gnomAD MAF (%)
RHBDL2	1	38941780	c.-224C>T	5'UTR		rs570057342	4		Hom	Het	0.05
CAP1	1	40039733	c.-1061C>T; c.-1079C>T	Promoter		rs1033279388	4		Hom	Het	not reported
SZT2	1	43427349	c.3331G>T	Exonic	p.D1111Y	rs887336448		27 (85)	Hom	Het	not reported
RNF149	2	101308657	c.-69C>G	5'UTR		rs78958738	4		Het	Hom	0.65
CHCHD6	3	126704425	c.87+26C>A	Intronic		rs768047544	2b		Het	Hom	0.00
MTRR	5	7889130	c.1263C>G; c.1182C>G	Exonic	p.D394E; p.D421E	rs149678769		8 (15)	Het	Hom	0.05
MBTPS1	16	84056017	c.2950G>A	Exonic	p.D984N	rs146299475		24 (65)	WT	WT	0.66
DGKE	17	56833747	c.-532A>C	Promoter		rs911884815	4		WT	Het	0.00
C17orf67	17	56833747	c.-1131T>G	5'UTR		rs911884815	4		WT	Het	0.00

# F. 2



# F. 3




# S. F. 2


## A

Human	Fly	Phenotype ( <i>Hand<sup>4.2</sup>; tdtK&gt;</i> )
Cofilin	tsr	lethal
		lethal
Profilin	chic	∅
		lethal
Arp2/3	Arp	↓ FS (↑ SD), moderate myofibrillar disorganization
		∅
Gelsolin	gel	↓ FS (↑ SD)
		∅
Transgelin	Chd64	∅
		↓ FS (↓ DD), moderate myofibrillar disorganization
WASP	WASp	↓ FS (↓ DD), strong myofibrillar disorganization
		↓ FS (↓ DD)
WIP	Verprolin 1	∅
		∅
Formins	DAAM	∅
		∅
Tropomyosin	Tm1	↓ FS (↑ SD)
		∅

## B




## C






# F. 4

Mito::GFP; Mef2-Gal4>



*Hand4.2>*

*Hand4.2-Gal4, Mito::GFP>*







**J** Diastolic Diameter- 1 week

**K** Systolic Diameter- 1 week

**L** Fractional Shortening- 1 week

**N**




**M** *Hand4.2; tdtK>*

Control<sup>A</sup>

ATPsynβ<sup>RNAiA</sup>

ATPsynB<sup>RNAiA</sup>

CHCHD3/6<sup>RNAiA</sup>




# S. T. 2


Mitochondrial functional group	Gene	RNAi line	Functional phenotype	Structural (F-actin) phenotype
ETC	ATPsynB (C.V)	RNAiA	↓ FS (↑ SD)	Yes
		RNAiB	↓ FS (↑ SD)	Yes
	ATPsynβ (C.V)	RNAiA	↓ FS (↑ SD)	Yes
	ATPsynγ (C.V)	RNAiA	↓ FS (↑ SD)	Yes
	ATPsynGL (C.V)	RNAiA	⊘	⊘
	blw (C.V)	RNAiA	↓ FS (↑ SD)	Yes
	ATPsynC (C.V)	RNAiB	↓ FS (↑ SD)	Yes
	mtND2 (C.I)	RNAiB	⊘	⊘
		RNAiC	↓ FS (↓ DD)	⊘
	ND-75 (C.I)	RNAiB	↓ FS (↑ SD)	⊘
	SdhC (C.II)	RNAiC	↓ FS (↓ DD)	⊘
	Cyt-c1 (C.III)	RNAiA	↓ FS (↑ SD)	⊘
		RNAiB	↓ FS (↑ SD)	⊘
	mtCo1 (C.IV)	RNAiB	⊘	⊘
RNAiC		↓ FS (↓ DD)	⊘	
Fission fusion	Drp1	RNAiA	⊘	⊘
	Marf	RNAiA	↓ FS (↑ SD)	⊘
		RNAiB	↓ FS (↑ SD)	⊘
	Opa1	RNAiB	↓ FS (↑ SD)	⊘
RNAiC		↓ FS (↓ DD)	⊘	
Cellular recycling	Park	RNAiA	⊘	⊘
		RNAiB	⊘	⊘
	Diap	RNAiC	⊘	⊘
Mitochondrial transporter	Rim2	RNAiA	⊘	⊘
		RNAiB	⊘	⊘
Mitochondria translation initiation factor	mIF2	RNAiC	↓ FS (↓ DD)	⊘
Heat shock protein chaperones 60	Hsp60A	RNAiC	⊘	⊘
Mitochondrial biogenesis	Srl	RNAiB	⊘	⊘
		RNAiC	⊘	⊘
Maintains cardiolipin	Taz	RNAiB	⊘	⊘

# S. F. 3


## A







## B



## C







# F. 5






# S. F. 4




# S. F. 5

## A



## B






# S. T. 3


Gene Symbol	Proband	Mode of Inheritance	Transcript variant	Protein variant	rsID	RegulomeD B Rank for regulatory variants	CADD score for missense variants (percentile )	gnomAD MAF (%)	Fly homolog	DIOPT score
CHCHD6	11H	homozygous recessive	c.87+26C>A		rs76804754 4	2b		0.001	CHCHD3/ 6	6
	158H	maternal	c.567-12104G>A		rs97050528 7	2a		0.023		
	228H	unknown	c.622T>C	p.Y208H	rs14502075 4		28 (90)	0.124		
CHCHD3	287H	maternal	c.524+1502C>G		N/A	2a		Not reported	CHCHD3/ 6	11
	199H	maternal	c.524+1429A>G;		rs91114992 7	4		Not reported		
	179H	de novo	c.370-1242A>T; *c.371A>T	*p.D124	N/A		18 (35)	Not reported		
	PCGC	transmitted	c.250C>T	p.R84X	rs88939398 8			0.0004		

# F. 6

## A Fractional Shortening- 1 week



## B Fractional Shortening- 1 week




## C

					Lethality	
Human gene	Fly gene	DIOPT	Function	RNAi line	Hand <sup>4.2</sup> , tdtK>	Hand <sup>4.2</sup> , tdtK; CHCHD3/6 <sup>RNAi1</sup> >
RNF149	Goliath	7	Ubiquitination, mesoderm formation	GoI <sup>RNAi1</sup>	0%	0%
				GoI <sup>RNAi2</sup>	0%	0%
Cdk12	Cdk12	11	Transcription, RNA splicing	Cdk12 <sup>RNAi1</sup>	47%	77%
				Cdk12 <sup>RNAi2</sup>	50%	88%
SPTBN1	β-Spectrin	15	Crosslinks with actin, scaffolding	β-Spec <sup>RNAi1</sup>	0%	0%

*Hand<sup>4.2</sup>, tdtK; CHCHD<sup>RNAi1</sup>>*

## D



# S. T. 4

A

CHCHD3 (PCGC)	CHCHD3 (199H)	CHCHD3 (179H)	CHCHD6 (11H)	CHCHD6 (158H)	CHCHD6 (228H)
ASIC5	BRPF3	LARGE	TTN	<b>SPTBN1</b>	LRP5
CCNB2	MCF2	TTN	RHBDL2	HNRNPAB	LZTS2
FMNL1	CDH12	POLD1	CAP1	KLHL4	RBM33
KMT2D	CMYA5	PLCL2	<b>RNF149</b>	RSBN1	SPEG
ZW10	NDUFS7	FARP1	MTRR	BUB1	MYH6
COG4	ZNF652	PTPRQ	MBTPS1	ANAPC1	FNDCA
COL6A6	PAN2	MAPK8IP3	DGKE	AADA2L2	
NT5C1B-RDH14		HNRNPU	MSI2	TRIO	
		SYNE1	PABPC4	DISP2	
		EP400	RNF220	ABR	
		NAA25	ZBTB20	TECR	
		MYH6	MAML3	HUWE1	
		KALRN	CDH13	GPM6B	
			ST3GAL3	AUTS2	
			CNOT11	NOTCH3	
			ITGA9	CACNA1C	
			TAGLN3	PDCD10	
			ADCY5	BCL2L11	
			ITGB5	CCDC3	
			NPRL2		
			NPRL3		
			EIF2S3		
			<b>CDK12</b>		
			HEG1		
			EBP		
			SZT2		
			C17orf67		
			PITPNB		
			PAN2		

No fly homolog

**Bold:** Interaction identified